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Abstract 
 
Advantages of fistulas, which include long patency and low complication rates, were 
ascertained over two decades ago and may not apply to the contemporary dialysis 
population. We conducted a systematic review to summarize the patency and 
complication rates of fistulas from literature published after 1999.  We screened 7,008 
citations and 62 articles met our criteria.  The risk of primary failure was 27% (95% 
confidence interval (CI): 23–32%). When primary failures were included, the primary 
and secondary patency rates were 59% (CI 53–64%) and 66% (CI 58–74%) at one year, 
respectively.  The median rates of infection, ischemic steal syndrome, and thrombosis 
were 0.11 (range 0.01–1.0), 0.05 (range 0.0–0.1), and 0.27 (range 0.04–0.68) events per 
1000 patient-days. When considering the fistula as the preferred option, the initial high 
risk of primary failure and complication rates should be considered alongside the long-
term benefits of using this access. 
 
Keywords 
arteriovenous fistula, fistula, hemodialysis, infection, ischemic steal syndrome, meta-
analysis, patency, primary failure, rates, steal syndrome, systematic review, thrombosis, 
vascular access 
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Chapter 1 : Introduction 
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1 Introduction  
Chronic hemodialysis is a form of renal replacement therapy that involves a dialysis 
machine which replaces or supplements the blood filtration and fluid removal role of the 
kidneys for patients with end-stage kidney disease (ESKD). Prior to starting 
hemodialysis, patients must have a vascular access inserted or created in the form of an 
arteriovenous fistula (fistula), arteriovenous graft (AV-graft), or central venous catheter 
(catheter). A vascular access provides the connection between the patient’s bloodstream 
and the hemodialysis machine. 
A complication-free, functioning vascular access continues to be the Achilles’ heel of 
hemodialysis therapy. The fistula is the preferred type of vascular access due to its longer 
patency or survival rate and lower complication rates.1–4 Use of a fistula is also associated 
with  lower mortality compared to the AV-graft and catheter.1–4 However, the advantages 
of the fistulas were ascertained over two decades ago and may not apply to the 
contemporary hemodialysis population. 
To describe fistula outcomes in the last decade we conducted two studies: 1) A 
systematic review, meta-analysis and meta-regression of the risk of primary fistula 
failure, primary fistula patency rate, and secondary fistula patency rate; and 2) A 
systematic review of fistula complication rates including infection, ischemic steal 
syndrome, and thrombosis. Our objectives were to efficiently summarize literature 
published between January 2000 and June 2012 on the fistula patency or survival and 
complication rates, as well as to identify existing knowledge gaps.  
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Chapter 2  
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2 Literature Review 
2.1 End-Stage Kidney Disease  
End-stage kidney disease (ESKD) occurs when the kidneys are no longer able to function 
at a level needed for day-to-day life.1 The burden of ESKD in Canada is growing; since 
1990, the incidence has increased by 58% and recently stabilized, while the prevalence 
has increased more than 200% and continues to grow.2 Patients with ESKD have a 
reduced health  related quality of life and a five-year mortality rate of less than 50%.3–6  
The treatment of ESKD is renal replacement therapy by means of a kidney transplant or 
dialysis (peritoneal dialysis or hemodialysis). 
The care of patients with ESKD is resource intense and places a heavy burden on the 
patient, family, and the healthcare system.7–10 For example, patients with ESKD represent 
0.11% of the Canadian population, however, Manns et al.8 reported 1.2% of all Canadian 
public health expenditure in 2002 was directed towards ESKD treatment.6 Using 
estimates from the Ontario Renal Network, the cost of hemodialysis management is 
approximately $500 million per year for approximately 11,000 patients.11 In 2009, the 
annual average Canadian cost of hemodialysis treatment was $60,000 per patient.12 It 
should be noted that this cost did not incorporate the cost of managing or diagnosing 
hemodialysis complications, surveillance of vascular access complications, and 
hemodialysis related-hospitalizations.  
Each patient with ESKD is uniquely affected by the burden attributed to social and 
economic changes. Similar to chronic diseases such as cancer and HIV, the number and 
severity of symptoms experienced by patients with ESKD contribute significantly to the 
patient’s quality of life.13,14  However, there are unique aspects related to hemodialysis, 
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that can affect the patient’s perception of his or her quality of life. For example, once on 
hemodialysis, patients have significant diet and fluid restrictions. Additionally, due to 
symptoms and time spent on hemodialysis, patients may experience changes in their 
employment status, recreational activities, and social roles. Being on hemodialysis may 
be financially burdensome to the patient and their families because of potential loss of 
income due time taken off work, travel to and from the dialysis facility, time spent on 
hemodialysis, as well as dialysis related transportation costs.  Further, a family member 
or a friend may be needed to help prepare the patient for dialysis, drive the patient to the 
dialysis facility, and help deliver them home safely, exerting a greater burden. In a cohort 
of patients (n=101 patients) at the London Health Science Center, Diamant et al.15 found 
that patients had to travel an average of 82 minutes to get to the dialysis facility and spent 
$42 per week on transportation. Furthermore, 86% of patients required an additional 
person (family/friend or other) to drive them to the dialysis facility.    
2.2 Modalities of Renal Replacement Therapy 
2.2.1 Kidney Transplantation 
Kidney transplantation is the preferred treatment option for ESKD. Approximately 40% 
of patients with ESKD in Canada have a pre-emptive transplant, and 3.5% of patients 
starting renal replacement therapy begin with this type of treatment.6 Transplantation is 
associated with improved patient quality of life, morbidity, mortality  and reduced burden 
on the healthcare system.12,16 Kidney allograft survival is approximately 94% at one year 
and 89% at two years when the organ is procured from a living donor.17,18 When the 
kidney is procured from a cadaveric donor, the allograft survival is 83% at one year and 
77% at two years.17,18 Compared to dialysis patients, individuals who receive a kidney 
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transplant have a 70% risk reduction in mortality and a dramatic improvement in quality 
of life.16,17 An economic analysis of patients with Type 1 diabetes and ESKD found that 
kidney transplantation was associated with 10.29 quality-adjusted life-years (QALY), 
whereas dialysis was associated with 4.52 QALY.19 Furthermore, patients will, on 
average, live 10 to 15 years longer with a kidney transplant compared to those on 
dialysis.16,19  However, not all patients are eligible or able to receive a kidney transplant.  
Currently, the number of kidney donations does not meet the demand for organs.20 In 
2005, transplant waitlists were increasing at a rate of 233 per million population in the 
United States, and 85 per million population in Canada.20 The corresponding transplant 
rates for the United States and Canada were 51 and 32 per million population, 
respectively.20 As a result, a large proportion of patients must undergo dialysis to replace 
kidney function.  
2.2.2 Dialysis 
Chronic dialysis is a form of renal replacement therapy that uses an internal or external 
non-kidney semi-permeable membrane filter that replaces or supplements the blood 
filtration and fluid removal role of the kidneys for patients with end-stage kidney disease. 
There are two types of dialysis: peritoneal dialysis and hemodialysis.  
2.2.2.1 Peritoneal Dialysis 
Approximately 10% of patients with ESKD in Canada are on peritoneal dialysis, and 
17% of patients starting renal replacement therapy begin with this type of treatment.6 In 
peritoneal dialysis, the non-kidney filter is the peritoneal membrane (an internal filter). 
An external catheter (hollow tube) is inserted into the abdominal cavity (peritoneum) and 
is used to fill the abdomen with dialysis solution (dialysate). The peritoneal membrane 
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filters waste products and extra fluid from the blood to the dialysate, which is then 
removed by drainage through the catheter. Peritoneal dialysis is usually performed in the 
home, but can be performed at work or in other environments, and offers patients the 
advantage of control and independence over the timing, duration and location of dialysis 
treatment. Utilization of peritoneal dialysis, however, may not be feasible in a proportion 
of patients due to medical and/or social contraindications.21  An increasing majority of 
frail and/or elderly patients are encountering barriers to self-care peritoneal dialysis.22–25 
Physical barriers include failing strength to lift peritoneal dialysis solution bags, poor 
vision, as well as immobility which are present in 37%, 25%, and 20% of the peritoneal 
dialysis population, respectively.26 As a result, such patients would require support from 
a family member and/or home care assistance to aid with peritoneal dialysis treatment. 
Physical and/or cognitive barriers and absence of an appropriate support system are 
important determinants of peritoneal dialysis eligibility.  
2.2.2.2 Hemodialysis 
Hemodialysis is the most common treatment modality for Canadian patients with ESKD. 
Approximately 50% of patients with ESKD in Canada are on hemodialysis, and 80% of 
patients starting renal replacement therapy begin with this type of treatment.6 
Hemodialysis removes waste products and excess fluid by passing blood through an 
external semi-permeable membrane within a hemodialysis machine. The hemodialysis 
machine consists of the filter “dialyzer”, dialysate solution, and a blood circuit which 
connects to the patient’s vascular access.  
Chronic hemodialysis is provided either in the home or in a dialysis facility (which may 
be attached to or independent of a hospital). In conventional hemodialysis, the patient 
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receives hemodialysis three to four times per week, for approximately three to five hours 
per session. For some patients, hemodialysis is prescribed five or six times per week for 2 
to 3 hours per session (frequent hemodialysis). Other patients are prescribed hemodialysis 
overnight for 6 to 8 hours per session (nocturnal hemodialysis) at a frequency of five to 
six times weekly. Regardless of the type of hemodialysis, the patient’s blood circulation 
must be connected to a dialysis machine via a vascular access. There are three traditional 
types of vascular access utilized, fistulas, AV-grafts, and catheters.  
2.3 Vascular Access 
2.3.1 Types of Vascular Access 
Arterio-venous (AV) fistulas are surgically created, typically in the patient’s non-
dominant forearm or upper arm by connecting an artery directly to a vein (Figure 1a). 
This anastomosis allows for higher blood flow directly from the artery through the vein. 
As a result, the vein distends and thickens over time (matures) allowing for repeated 
needle cannulations for hemodialysis treatment. Thus, creation of a fistula requires 
advance planning because it can take up to six months to mature and be used for 
hemodialysis. 
AV-grafts are also surgically created by using a synthetic tube to connect the arterial and 
venous circulations (Figure 1b). The AV-graft becomes an artificial vein that can be used 
for repeated cannulation and blood access for hemodialysis. Unlike the fistula, the AV-
graft does not need to mature. However, traditional AV-grafts require two to three weeks 
for swelling and bruising to subside before use. 
Catheters are inserted into the patient’s internal jugular, subclavian, or femoral vein. The 
most common placement is the internal jugular vein in the neck (Figure 1c). Catheters 
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are indicated for same day placement and immediate use for hemodialysis. Furthermore, 
hemodialysis patients who are not suitable for creation of an arteriovenous access (fistula 
or AV-graft) will use a catheter.       
 
Figure 1. Types of vascular access: a) arteriovenous fistula [fistula] b) arteriovenous 
graft [AV-graft], and c) central venous catheter [catheter] 
2.3.2 Burden of Vascular Access 
Vascular access and its associated complications are significant contributors to rising 
morbidity, mortality, reduced patient quality of life, and burden on the healthcare 
system.10,20,27,28 Complications such as thrombosis (blood clots in the vascular access), 
and infections account for nearly 30% of hospital admissions in hemodialysis 
patients.9,27,29 These complications consume a significant proportion of outpatient 
resources including vascular access monitoring and diagnostic radiology.9,27,29 Manns et 
al.10 reported the mean cost of access care during the first year of dialysis per patient-year 
at risk was $7,989 for a fistula, $11,685 for an AV-graft, and $9,180 for a catheter. These 
costs included cost of surgery, radiology, hospitalization for access complications, 
Source: From Google 
Fistula AV-graft Catheter 
> > 
a b c 
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physician services, management of outpatient bacteremia, and vascular access 
monitoring. 
2.3.3 Comparing Outcomes of Patients Receiving Hemodialysis by 
Vascular Access Type 
Clinical practice guidelines strongly advocate for the fistula as the preferred vascular 
access.30–32 Fistula use has been associated with lower morbidity and mortality compared 
to both AV-grafts and catheters. The preferred vascular access placement (in order of 
preference) is radiocephalic fistula (at the wrist), brachiocephalic fistula (at the elbow), 
transposed brachiobasilic fistula (upper arm), followed by a forearm loop AV-graft, 
upper arm AV-graft, lower extremity AV-graft, and finally with catheters being least 
preferred option.30–32  In Section 2.3.3.1 to Section 2.3.3.3, we compare the risk of 
patient mortality and hospitalization between each type of vascular access.  
2.3.3.1 Catheters versus fistulas 
Mortality 
In a study of 4,196 incident patients (number of patients: fistula=626; catheter=3,570), 
Wasse et al.33 found that there was a statistically significant decrease in the all-cause 
mortality comparing patients using a fistula to those using a catheter. Patients who used a 
fistula had a 29% hazard reduction (HR=0.71; 95% CI 0.62 to 0.82) in all-cause mortality 
compared to patients who used a catheter. Using Canadian data, Moist et al.34 found that 
there was a 37% (RR=0.63; 95% CI 0.57 to 0.69) risk reduction in all-cause mortality 
when comparing patients using a fistula or AV- graft to initiate dialysis compared to 
those using a catheter. Examining cardiovascular-related mortality, the adjusted (for age, 
sex, race, and co-morbidities) hazard ratio was 0.69 (CI 0.56 to 0.84) for patients who 
used a fistula compared to those who used a catheter at 90 days after initiating dialysis. In 
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a propensity score matched cohort (n=1,479),  Polkinghorne et al.35 reported an all-cause 
mortality rate of 115 per 1000 person-years ([CI 94 to 142; 90 deaths) in patients with 
fistulas and 242 per 1000 person-years (CI 211 to 277; 209 deaths) in patients using a 
catheter. Results from a systematic review and meta-analysis from 62 studies (n=586,337 
patients) collected between 1985 and 2011, Ravani et al.36 reported a 53% risk increase 
(RR=1.53; CI 1.41 to 1.67) in all-cause mortality comparing patients using catheter to 
those using a fistula. 
Hospitalization 
Catheter use is associated with an increased risk of infection-related complications, 
RR=2.77 (CI 1.83 to 4.21) and vascular access-related hospitalization, RR=3.10 (CI 2.05 
to 4.68) when compared to fistula use.37 Patients using a catheter had a rate of 38.8 (35 to 
44) hospitalizations per 100 person-years, while patients using a fistula had a rate of 23.8 
(CI 17 to 32) hospitalizations per 100 person-years.37 This relation of increased risk of 
hospitalization is also consistent across facilities with higher catheter use. Facilities with 
higher catheter use have been shown to be an independent predictor of hospitalization 
risk, even after adjusting for patient demographics, laboratory values, and 
comorbidities.38,39 Data from the Dialysis Outcomes and Practices Patterns Study 
(DOPPS) show that facilities with >21% of patients using a catheter had a 1.6 fold 
increased risk of hospitalization as a result of infections compared  facilities with ≤7% of 
patients using catheters.38 In a meta-analysis, Ravani et al.36 found a 68%increased risk 
(RR=1.68; CI 1.33 to 2.12) of hospitalization comparing patients using a catheter to those 
using a fistula. Furthermore, patients who dialyzed using a catheter spent on average 1.7 
to 3.7 times longer period in a hospital compared to those who used a fistula.40 
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2.3.3.2 Catheters versus AV-grafts 
Mortality 
Polkinghorne et al.35 investigated the risk of mortality between prevalent catheter and 
AV-graft use in the Australian and New Zealand Dialysis and Transplant Association 
(ANZDATA) registry data. Polkinghorne et al.35 reported a 67% (RR=1.67; CI 1.15 to 
2.43) risk increase in all-cause mortality comparing those using a catheters versus AV-
grafts.  The crude rate of all-cause mortality was 261 (CI 233 to 293) deaths per 1000 
person years for catheters, and 146 (CI 115 to 185) deaths per 1000 person-years for AV-
grafts.35 When examining only diabetic patients, two studies reported different results in 
regards to the risk of all-cause mortality between those using catheters versus AV-grafts.  
Allon et al.41 reported a relative risk of all-cause mortality of 3.11 (CI 2.31 to 4.19), while 
Dhingra et al.,28 reported a RR of 1.09 (CI 0.77 to 1.54) for all-cause mortality comparing 
diabetic patients using a catheter versus an AV-graft. In a meta-analysis comparing 
catheters to AV-grafts, Ravani et al. reported a 38% risk increase (RR=1.38; 1.25 to 1.52) 
in all-cause mortality.   
Hospitalization 
Among patients who were hospitalized for any reason, those using a catheter spend on 
average 6.9 (CI 0 to 24) days in the hospital compared to 6.6 (CI 0 to 25) days for 
patients using an AV-graft.37  Catheters are at high risk of vascular access-related 
infections and infection-related hospitalization. For example, there is a 40% increase in 
the risk of hospitalization for patients using catheters compared to those using an AV-
graft.37 Patients dialyzing with a catheter at baseline experience a hospitalization incident 
rate of 170 per 100 person-years (CI 160 to 180) compared to 121 per 100 person-years 
for AV-grafts (CI 108 to 136).42 Ravani et al.36 reported a pooled relative risk of 1.51 (CI 
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1.30 to 1.75) in all-cause hospitalization comparing patients using a catheter to those 
using an AV-graft.  
2.3.3.3 AV-grafts versus fistulas 
Mortality 
There is conflicting results on all-cause mortality when comparing AV-grafts to fistulas. 
Polkinghorne et al.35 reported a crude all-cause mortality of 86 (CI 76 to 98) deaths per 
1000 person-years for fistulas compared to 146 (CI 115 to 185) for AV-grafts.  After 
adjusting for morbid conditions and propensity score, there was a 1.55 (CI 1.15 to 2.07) 
hazard ratio for all-cause mortality comparing AV-grafts to fistulas.35 The authors 
stratified on the presence of coronary artery disease and adjusted for age, gender, late 
referral, peripheral vascular disease, and cerebral vascular disease. Similarly, in a study 
of 25,226 patients, Xue et al.43 reported a significant increase in the risk (RR=1.16; CI 
1.08 to 1.24) of all-cause mortality when comparing patients using AV-grafts and 
fistulas. However, we identified five studies that found no association between type of 
arteriovenous access (fistula or AV-graft) used and all-cause mortality.28,33,41,44,45 
Although there is a lack of consensus across studies, there is a consistent trend towards a 
higher risk of all-cause mortality comparing patients using an AV-graft versus a fistula. 
In a meta-analysis, Ravani et al.36 found an 18% (RR=1.18; CI 1.07 to 1.27) increase in 
the risk of all-cause mortality when comparing individuals using an AV-graft to those 
using a fistula.  
Hospitalization 
Using a random sample of 2635 incident patients from the United States, patients using 
an AV-graft at baseline experienced a hospitalization incidence rate of 121 (CI 108 to 
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136) compared to 104 (CI 90.5 to 118) per 100 person-years for patients using a fistula.37 
When comparing AV-grafts and fistulas within the first six months of hemodialysis start, 
there was no difference in the risk all-cause hospitalizations (RR=1.15; CI 0.94-1.40).  
However, when exploring risk of specific hospitalizations, AV-grafts had a 91% 
increased risk of vascular access-related hospitalizations compared to patients using a 
fistula.37 Indeed, these results were further supported by Pisoni et al.39 using facility data 
collected by DOPPS. The authors reported a 10% greater risk (RR=1.10; CI 1.02 to 1.19) 
in all-cause hospitalizations for every 20% greater facility use of AV-grafts. As expected, 
the authors also found a substantially greater risk of vascular access-related 
hospitalizations among facilities with greater use of AV-grafts.39 Pooling results of all-
cause hospitalizations in a meta-analysis, Ravani et al.36 found that individuals using an 
AV-graft had a 26% increase (RR=1.26; CI 1.13 to 1.40) in the risk of all-cause 
hospitalization compared to those using a fistula. The increased risk of hospitalization is 
postulated to be due to the higher risk of thrombosis, as well as vascular access-related 
infections associated with AV-grafts.   
2.3.3.4 Limitations of Studies Included Above 
Studies comparing vascular access types are generally observational in nature and 
susceptible to high risk of bias and confounding by indication. Ravani et al.36 found that 
among studies reporting on vascular access, the description of methods was generally 
incomplete and all studies were at moderate or high risk of bias, especially selection bias. 
To assess study quality, Ravani and colleagues addressed two questions for each quality 
domain to define the risk of bias. The risk of bias for each domain was defined as low if 
the answer was ‘Low Risk of Bias’ for both questions; moderate if only one was ‘Low 
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risk of bias’ and the other ‘High risk of bias’ or ‘unclear’; and high if neither was ‘Low 
risk of bias’ (i.e. both answers were ‘High risk of bias’ or ‘unclear’). Furthermore, the 
current evidence for vascular access must be interpreted with caution due to the high 
degree of heterogeneity between studies.  There are a number of factors that may 
contribute to this heterogeneity including variability in monitoring, vascular access care, 
and patient case mix. Currently, there are no randomized control trials that evaluate the 
benefits and harms of hemodialysis vascular access.36  Therefore, the current vascular 
access literature provides low-quality observational evidence that is vulnerable to 
confounding by measured and unmeasured variables.  
2.3.4 Vascular Access Trends  
Placement of the appropriate vascular access for each patient is a key priority in order to 
minimize complications, thereby reducing associated costs, morbidity and mortality. 
Vascular access clinical performance measures,46 and initiatives such as the “Fistula 
First”47 all share the common goal of optimizing management of vascular access and 
increasing the appropriate creation and subsequent use of fistulas. These initiatives aim to 
increase fistula use to >60-65% among prevalent patients.30,47 Globally, Canada has 
consistently had one of  the lowest rates of fistula use.48 In 2010, Canadian registry data 
revealed that only 17% of incident and 46% of prevalent hemodialysis patients dialyzed 
using a fistula (Figure 2 and 3). The use of AV-grafts was 1% among incident and 4% 
among prevalent patients (Figure 2 and 3). The low fistula and AV-graft incident use has 
remained unchanged since 2001. However, the prevalent use continues to progressively 
decline, despite the recommendations from the clinical practice guidelines.  
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Figure 2. Incident vascular access use among Canadian adult patients ≥18 years.6  
 
Figure 3. Prevalent vascular access use among Canadian adult patients ≥18 years.6 
 
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
90.00%
100.00%
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Catheter Fistula AV-graft
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Catheter Fistula AV-graft
18 
 
2.3.5 Barriers to Optimal Vascular Access Creation and Use 
2.3.5.1 Aging hemodialysis population with increasing numbers 
and complexities of comorbidities  
Older age and increased comorbidities are important determinants in the use of an 
arteriovenous access. There is a large body of literature associating low rates of fistula 
use among the elderly (age >65), females, Caucasians, and those patients with diabetes, 
peripheral vascular disease, and coronary artery disease.48–51 It makes pathophysiologic 
sense for older age and co-morbid conditions to impact fistula use because adequate 
blood inflow and output are required for fistula maturation and would be hampered by 
diseased vasculature and poor cardiac output.52 The changing patient demographics and 
the increasing proportion of frail and/or elderly patients in the recent decade may further 
decrease fistula creation and performance. Indeed, 58% of Canadian patients starting 
hemodialysis were ≥ 65 years of age in 2011, compared to 33% in 1990.53  Given the 
aging hemodialysis population and the increase in accompanying complexities of 
comorbidities, it would not be surprising to see arteriovenous access creation, 
performance or use decrease overtime. 
2.3.5.2 Difficulty predicting the rate of kidney loss and when to 
initiate hemodialysis, as such, the optimal timing for 
arteriovenous access creation is challenging 
It is difficult to accurately determine the optimal timing of vascular access creation as 
timing of dialysis initiation is difficult to predict. In fact, hemodialysis initiation is 
unplanned in up to 50% of patients, primarily because of late ESKD diagnosis, urgent 
medical indications, or acute inter-current illnesses in a patient with chronic kidney 
disease.54–57 Patients with unplanned dialysis starts usually initiate dialysis with a 
catheter. Additionally, the competing risk of death exceeds the rate of progression to 
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ESKD  among the elderly with chronic kidney disease.58 Thus, if a vascular access was 
created in all patients at a certain level of kidney function, a significant number of 
patients would die before starting dialysis. This utilizes limited resources that could 
otherwise be used for patients who might benefit. Therefore, in the elderly, one has to 
estimate the risk of dying compared to the risk of starting dialysis. For example, data 
from Veterans affairs estimates that if all patients over age of 80 years had an access 
created at a estimated glomerular filtration rate <25 ml/min/1.73m2, only one patient out 
of six would in fact use their vascular access for dialysis.59 In an Ontario study, 9% of 
patients who had an arteriovenous access created during the pre-dialysis period died 
before needing hemodialysis and another 10% never required dialysis after a follow-up of 
39 months.60 This means 19% of arteriovenous accesses were created too early in the 
course of chronic kidney disease progression and were unnecessary procedures.  
2.3.5.3 Late nephrology referral or urgent hemodialysis starts 
Late nephrology referral (<3 months of nephrology care prior to dialysis start) is 
associated with unplanned dialysis starts, higher catheter use, and adverse health 
outcomes.61–64 This is not surprising as fistulas may take up to 6 months to mature. Thus, 
late nephrology care limits the planning and preparation time to creating an arteriovenous 
access. In contrast, adequate pre-dialysis care takes months to years in order to prepare 
the patient for living with chronic kidney disease and help the patient decide on modality 
choice (pre-emptive kidney transplant versus peritoneal dialysis versus hemodialysis) 
before a patient can be appropriately referred for dialysis access assessment. Beyond this 
process, time is required for surgical consultation, operation room booking, and 
unexpected cancellations. Appropriate pre-dialysis care and arteriovenous access 
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placement has been shown to reduce risk of mortality. However, the benefit of early 
nephrology care is negated by initiating hemodialysis using a catheter.65 
2.3.5.4 Suboptimal pre-dialysis care, including lack of process to assist 
patient decision makings, identifying suitable patients for an 
arteriovenous access, and a shortage of surgical and radiological 
expertise and resources  
Although 60% to 70% of new patients with ESKD in Canada are seen by a nephrologist 
≥12 months before starting hemodialysis,51 only 20% of patients initiate hemodialysis 
using an arteriovenous access. Barriers to arteriovenous access creation exist at the health 
care organizational, institutional, provider, and patient levels. These barriers of vascular 
access creation even exist among those under a nephrologist’s care in the chronic kidney 
disease clinic. At the patient level, patients with chronic kidney disease face many 
decisions about the type of dialysis modality they want (hemodialysis, peritoneal dialysis 
or transplant), and other pressing issues as they start dialysis, often delaying the process 
in arteriovenous access creation.66–68 
Patient delays and sub-optimal process of arteriovenous access creation is further 
complicated by lack of resources and access to timely radiological and surgical care.51,69 
In a Canadian study, system/resource limitations had the greatest influence on catheter 
use within the first six months of hemodialysis.69 Compared to Europe and the United 
States, Canada has fewer vascular access surgeons per 100 hemodialysis-patients, and 
consequently less hours devoted to vascular access surgery.51  
Canadian nephrologists were asked to identify barriers to arteriovenous access use among 
incident and prevalent patients.70 The majority of nephrologists felt patient delays in 
decision making, patient refusal of arteriovenous access creation, and long wait times for 
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surgical and radiological care contributed substantially to barriers achieving a functional 
arteriovenous access. Studies suggest that having a defined care pathway that includes 
dialysis modality education (Figure 4), higher estimated glomerular filtration rate 
thresholds for surgical referral, and a patient tracking database can lead to timely vascular 
access placement and improve patient outcomes.71 In contrast, the tension with the 
unnecessary procedures and cost, and other studies indicating lack of significant benefit 
of long term follow-up in pre-dialysis with regards to initiating dialysis with an 
arteriovenous access, highlights the need to study specific process gaps, failures and 
successes in a rigorous manner. 
 
Figure 4. Defined care pathway that includes dialysis modality education, higher eGFR 
(estimated glomerular filtration rate) thresholds for surgical referral and fistula 
placement. AV=Arteriovenous; CKD= Chronic Kidney Disease; ESRD=End-stage Renal 
Disease; ESKD=End-Stage Kidney Disease; HD=Hemodialysis; RRT=Renal 
Replacement Therapy; VA=Vascular Access 
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2.3.5.5 High rates of arteriovenous access failure and non-suitability for 
dialysis once created 
As defined by a previous study,52 several decades ago, fistulas had acceptable risk of 
primary failure ranging between 10% to 24%72–75 and 1-year primary and secondary 
patency rates between 65% to 94%74,76–78 and 85% to 90%, respectively.79 Compared to 
data published prior to 2000, there has been a significant decrease in the performance of 
fistulas over time, with current data suggesting primary failure rates of 24% to 60%.80–88 
The 1-year primary and secondary patency rates from recent published literature range 
between 43% to 87% and 52% to 89% respectively.81,82,85,86,88–92 Older age (>65 years), 
coronary artery disease, and peripheral vascular disease are some of the clinical factors 
that are  consistently associated with the increase risk of arteriovenous access failure and 
as a result lead to catheter use.49,71,93  
2.3.5.6 Variability of practice patterns 
Both surgical creation and nursing cannulation experience and skill set independently 
impacts arteriovenous access creation, dialysis suitability, and maintenance. However, 
there is a wide variation in practice patterns that exist between regions and individual 
dialysis programs in terms of emphasis on types of vascular access placement and care.  
Data from the DOPPS  show marked variation in the number of vascular accesses created 
and emphasis on vascular access education among surgical training programs.94 There 
were marked differences across countries regarding number of vascular access surgeons 
per hemodialysis unit, number of vascular access placed during surgical training, and 
number/type of vascular access creations per surgeon in the preceding 12 months. A 
greater number of fistula placement during surgical training was an independent predictor 
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for patients receiving a functional access in practice. Surgeons who created at least 25 
fistulas during their surgical training had a 34% lower risk of creating fistulas that had a 
primary failure compared with those with <25 fistula creations.94 
In addition to surgical expertise, nursing cannulation skills and experience with 
arteriovenous access care has a paramount influence on vascular access-related outcomes. 
Cannulation skill and the level of vascular access care provided by the dialysis nurse 
affects the risk of complications and have a vital role in patient satisfaction.95 A deficit in 
nursing experience can cause an increase patient dissatisfaction, pain during needling, 
prolonged vascular access bleeding, as well as clotting and infections.95 It is well 
established that procedural skills require a minimal set time per week of performing the 
skill to maintain its proficiency.96 In an environment where ≥80% of patients initiate 
dialysis with a catheter, nurses are likely to lose their cannulation skills, resulting in 
damaged arteriovenous accesses and a further prolonged dependence on catheters. 
2.3.6 Factors Affecting Long-term Fistula Outcomes 
The natural development of the fistula includes remodelling of the vein once the 
arteriovenous anastomosis has been created and as a result may favour stenosis and 
eventually thrombosis. During the process of maturation, there is a significant increase of 
blood flow. Initial blood flow rate within the radial artery increases from 20-30 ml/min 
before fistula creation to 200-300 ml/min immediately after surgical creation of the 
fistula.97 This flow rate increases to 600-1200 ml/min in a few weeks after surgery, 
provided there are no complications and the blood vessels are healthy.97,98  In a series of 
17 radiocephalic fistulas, Lemonte et al.99 reported that blood flow through the brachial 
artery to the fistula was >480 mL/min at 28 days post-surgical fistula creation. This 
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suggests that a clinical assessment of fistula development can be made at 4 to 6 weeks 
after creation.100 In fact, there are programs that evaluate fistula maturation as early as 
one month post-surgical construction.101 Fistulas failing to achieve adequate (>500 
mL/min) flow rates by 6 to 8 weeks will likely require surgical/radiological interventions 
or perhaps a creation of a second permanent access in the event the fistula is not 
salvageable.30   
Not surprisingly, fistula failure can be expected to occur when the vessel wall is either 
not ready to be used (non-maturation), is damaged (due to poor surgical creation, as well 
as early and/or unskilled cannulation), becomes abnormal (atherosclerosis, calcification, 
and/or fibrosis/stenosis), and/or when the blood and/or the vessel walls contain 
coagulating factors favouring fibrin formation and platelet aggregation.98 As discussed 
above (Section 2.3.5.5), several clinicopathological risk factors have emerged from 
observational studies that can be incorporated in assessment for risk of fistula failure.49 
Although inconsistent results have been observed, gender, age, diabetes, and cancer, for 
example, are associated with higher risk of fistula failure.93,102–104 Conversely, 
cardiovascular disease, late referral to nephrologist, and previous radiological 
intervention of the fistula or catheter use are consistently associated with shortened fistula 
patency even after adjusting for co-morbid conditions and other prognostic factors.105,106 
These factors shed light on the importance of referring patients early to a nephrologist for 
timely assessment and placement of a permanent vascular. Additionally, these factors 
become increasingly important when screening for eligible patients for fistula creation.   
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3 Patency Rates of the Arteriovenous Fistula for 
Hemodialysis: A Systematic Review and Meta-Analysis 
3.1 Introduction  
Hemodialysis clinical practice guidelines endorse the arteriovenous fistula (fistula) as the 
preferred form of vascular access. Its use is associated with fewer complications, 
improved access survival, and lower risk of mortality compared to an arteriovenous graft 
or central venous catheter.1–3 However, the fistula has a high risk of primary failure due 
to early thrombosis and maturation failure.4,5 The changing patient demographics and the 
increasing proportion of frail, elderly patients in recent decade, may further decrease 
fistula performance. Indeed, 58% of Canadian patients starting hemodialysis were ≥ 65 
years of age in 2011, compared to 33% in 1990.6  Estimates of primary fistula failure, as 
well as primary and secondary patency vary considerably in the literature (standardized 
definitions of these outcomes are presented in Box 1). Recent reports estimate primary 
fistula failure and 1-year primary patency to range between 30% to 70% and 40% to 
70%, respectively.7–11   
Knowledge of fistula performance not only informs patient consent and quality 
improvement initiatives but more importantly guides patient and clinician decision-
making. A better understanding of fistula performance can help explain the discrepancy 
in fistula use between best practice recommendations and current practice, and help re-
evaluate standards for what is deemed “best practice”.12 In the present study, we 
conducted a systematic review and pooled estimates of primary failure, as well as 
primary and secondary patency rates (1 and 2-year) from prospectively collected data 
published between January 2000 and June 2012.   We aimed to improve the precision of 
39 
 
fistula performance estimates, as well as explore the influence of study and patient 
characteristics on the overall parameter estimates. In subgroup analyses, we examined the 
effect of fistula location (lower vs. upper arm), age (elderly vs. non-elderly), and location 
of study (North America vs. Europe) on primary failure, primary patency, and secondary 
patency rates.  
3.2 Methods 
We conducted and reported this systematic review according to published guidelines 
using a pre-specified protocol (MOOSE Checklist: Appendix A).13,14 
3.2.1 Studies Eligible for Review 
We formulated study inclusion and exclusion criteria a priori. We included any study that 
collected data prospectively (observational cohort studies or randomized control trials) 
and followed patients for at least 3 months.  We only deemed studies eligible if they 
described ≥100 fistulas in patients with chronic kidney disease. We included only full-
text English-language articles published after December 31st, 1999. Studies must have 
reported information on one or more of the following: a) primary failure; b) primary 
patency (1 and/or 2-year); c) secondary patency (1 and/or 2-year). We excluded studies of 
peritoneal dialysis and pediatric patients (<18 years). 
3.2.2 Study Definitions 
Unless otherwise specified, all vascular access definitions were in accordance with the 
Society of Vascular Surgery and the American Association of Vascular Surgery and the 
North American Vascular Access Consortium  (NAVAC)  (Box 1).4,15 When definitions 
were not in agreement between the two documents, we used the NAVAC definitions. 
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When an outcome definition was unclear, not reported, or different from the above 
definitions it was documented within our tables. 
Box 1: Outcome Definitions 
 
• Primary failure: immediate failure of fistula within 72 hours of surgery, 
early dialysis suitability failure, or late dialysis suitability failure.4  
o Early dialysis suitability failure: This is an access that, despite 
radiological or surgical intervention, cannot be used successfully for 
dialysis by the third month following its creation.  
o Late dialysis suitability failure: This is an access that, despite 
radiological or surgical intervention, cannot be used successfully for 
dialysis by the sixth month following its creation.  
• Primary patency: the interval from the time of access creation until first 
access thrombosis, or any intervention to maintain or restore blood flow.4,15  
• Functional primary patency: the time from the first successful two-needle 
cannulation until first intervention or access failure.4,15 
• Secondary (cumulative) patency: the time from access creation until access 
abandonment. Secondary patency was not terminated by surgical or 
interventional radiology procedures to maintain or restore patency.4,15 
• Functional secondary patency: the interval from first successful two-needle 
cannulation for hemodialysis treatment to access abandonment.4,15 
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3.2.3 Data Sources and Study Selection 
We designed and implemented a systematic literature search to identify all relevant 
published reports in Medline (OVID and Pubmed) from January 1st 2000 to June 30th 
2012. The search strategy included a combination of key and MeSH words (Appendix 
B). We also used related articles features in PubMed. One investigator (A.A.) screened 
all titles and abstracts obtained through the search syntax to identify potentially relevant 
articles. We retrieved the full-text of these articles to further assess their suitability for 
inclusion in this review. Bibliographies of selected articles were searched manually to 
identify any additional relevant studies. 
3.2.4 Data Extraction and Quality Assessment 
Two reviewers (A.A. and either J.C.Z., S.D.K., or S.M.T.) independently extracted data 
using a standardized form. This was done in duplicate to increase accuracy and reduce 
measurement bias. If extracted data differed between the two reviewers, we resolved 
disagreement by consensus or with the help of a third reviewer (J.C.Z or S.M.T). We 
extracted data on the following: a) study characteristics including the year of publication, 
country, study design, and number of fistulas; b) methodological characteristics such as 
outcome definitions, follow-up period, and loss to follow-up; c) patient characteristics 
including location of upper extremity fistulas, mean age, mean time between fistula 
creation and two-needle cannulation, as well as proportion of men, Caucasians, patients 
with peripheral vascular disease, diabetes, and upper arm fistulas; d) assessed risk of bias 
among included studies, exploring participation, patient selection, attrition, exposure and 
outcome measurements, and confounding using a previously validated method;16 and  e) 
primary failure and/or patency rates as defined above (Box 1) [Note: The term “rate” 
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reported here is not a true rate {i.e. event per person-time} but used because of 
convention in the literature]. Most studies reported patency rates using life tables or in the 
text of the article, as opposed to Kaplan-Meier curves. When patency rates were only 
reported using Kaplan-Meier plot, we estimated the patency rate from the curve.  
3.2.5 Data Analysis 
The primary outcomes were rates of primary failure, primary patency, and secondary 
patency. Secondary outcomes were rates of functional primary patency and functional 
secondary patency.  We calculated the 95% confidence interval (CI) for each study 
estimate using the Wilson Score method.17 The Wilson Score interval has been shown to 
provide excellent coverage and has better performance than the standard Wald 
interval.18,19 
We pooled the rates of primary failure, as well as rates of primary and secondary patency 
using a random effects model. We used the I2 statistic to test for heterogeneity in risk 
estimates across studies.20 We recorded and analyzed estimates separately for clinically 
important subgroups. We calculated the pooled estimate for pre-specified subgroups 
including fistula location (lower vs. upper arm), age (elderly vs. non-elderly as defined in 
the selected study), as well as study location (North America vs. Europe).  We performed 
the analysis using SAS 9.2 (SAS Institute Inc., Cary, NC, USA) PROC MIXED 
procedure. This method allowed us to specify covariates in random effects univariable 
meta-regression. We explored heterogeneity between risk estimates according to the 
mean patient age, proportions of men, diabetic patients, and patients with peripheral 
vascular disease, number of fistulas, proportion of upper arm fistulas, country study was 
performed, recruitment start date, and publication year. In sensitivity analysis, we 
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excluded studies that were published after 2000 but recruited patients prior to 2000, 
sample size was <100 fistulas, studies that asked study question after data collection (i.e. 
retrospective design). We performed additional sensitivity analyses for patency rate and 
excluded studies that did not report if primary failures were included/excluded in the 
patency calculation.  In order to justify our analyses, we required at least three 
independent estimates per subgroup. We used a two-sided p-value and considered a p-
value <0.05 to be statistically significant. 
3.3 Results 
3.3.1 Included Studies 
We screened 7,008 citations and retrieved 459 full-text articles to assess for eligibility. 
Forty-two articles met our criteria for review; however, two studies were excluded due to 
insufficient information on study design.22,23 Three eligible articles were published using 
data from United States Renal Data System Dialysis Mortality and Morbidity Wave II 
(USRDS); however, since study patients among these articles significantly overlapped, 
we only included results from the study with the largest sample of fistulas.24–26 Details of 
the study selection are shown in Figure 5. We identified five additional studies through 
manual search of bibliographies of selected articles. Thus, we included 43 articles (41 
studies) reporting on 61 cohorts (59 unique cohorts; n=11 868 fistulas), published after 
January 1st 2000 with patient recruitment between 1985 and 2008. The characteristics of 
each article are described in Table 1 and Table 2. Seventeen studies reported outcomes 
from the United States, five from each of Italy and United Kingdom, four from each of 
Canada and Netherlands, three from Turkey, and one each from Croatia, Saudi Arabia, 
and Slovenia.  One additional article by the Dialysis Outcomes and Practice Patterns 
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Study (DOPPS) examined fistula outcomes from European countries in DOPPS.27 
Follow-up was not reported for 30 cohorts.  In the remaining 31 cohorts; the median loss 
to follow-up was 3% (range 0% to 22%; interquartile range [IQR] =8%). 
 
Figure 5. Flow diagram of study eligibility and inclusion. CKD= Chronic Kidney 
Disease; RCT=randomized controlled trial.
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Table 1. Study Characteristics 
Author Year Country 
Recruitment 
Start 
Cohort 
Characteristics 
Follow-up 
(Mths) 
Number of 
Access 
Upper 
Arm* 
(%) 
Age 
(years) 
Male 
(%) 
White 
(%) 
DM 
(%) 
PVD** 
(%) 
Quintaliani et al.41 2000 Italy . Lower Arm 41 124 0% 57.5 56% . 0% . 
Wolowczyk et al.42 2000 UK 1985 Lower Arm . 208 0% 63.0 55% . 14% . 
Allon et al.9 2001 USA 1998 All . 138 46% . 64% 40% 54% . 
Gibson et al.43 2001 USA 1996 All 11 492 . 66.0 53% 66% 54% . 
Dixon et al.10 2002 USA 1992 Lower Arm . 88 0% 52.0 82% 95% 45% 15% 
Dixon et al.10 2002 USA 1992 Upper Arm . 117 100% 59.0 55% 54% 52% 28% 
Huber et al.44 2002 USA 1999 All . 117 75% 53.0 51% 60% 49% . 
Malovrh45 2002 Slovenia 1993 All 3 116 . 51.4 47% . . . 
Pisoni et al.27 2002 USA 1996 USA . 177 . 60.5 53% 62%○ 46% 23% 
Pisoni et al.27 2002 Europe 1998 Europe . 429 . 60.7 57% 99%○ 22% 19% 
Puskar et al.46 2002 Croatia 1992 All . 463 5% . 58% . 6% . 
Ravani et al.47 2002 Italy 1995 All 20 197 19% 65.7 59% . 22% . 
Feldman et al.48 2003 USA 1994 All . 237 . 56.0 68% . 34% . 
Bonforte et al.49 2004 Italy 1991 Lower Arm 27 112 0% 71 50% . 22% . 
Perera et al.50 2004 USA 1999 All . 100 50% 55.0 75% . 50% . 
Ravani et al.51 2004 Italy 1997 All 42 513 . 66.3 58% 98% 27% . 
Zeebregts et al.52 2004 NLD 2000 Clip 15 51 0% 58.9 69% . 19% . 
Zeebregts et al.52 2004 NLD 2000 Suture 11 56 0% 58.9 69% . 19% . 
Lok et al.53 2005 Canada 1995 Elderly . 196 53% 74.0 69% 69% 30% 10% 
Lok et al.53 2005 Canada 1995 Non-elderly . 248 43% 46.0 65% 63% 29% 8% 
Manns et al.54 2005 Canada 1999 All . 157 40% 63.6 72% . 48% 22% 
Vernaglione et al. 
55
 2005 Italy 1995 Lower Arm 42 105 0% 63.8 52% 100% 23% 19% 
Wells et al.56 2005 UK 2002 All . 136 28% . 70% . 17% . 
Zeebregts et al.57 2005 NLD 1999 Upper Arm 20 100 100% 59.2 59% . 24% . 
Elsharawy58 2006 
Saudi 
Arabia 2003 All . 126 69% 36.0 64% . 41% . 
Erkut et al.59 2006 Turkey 1995 Lower Arm 47 298 0% 45.0 75% . 12% . 
Lok et al.7 2006 Canada 1995 
Derivation 
Cohort 6 422 39% . . . . 16% 
Lok et al.7 2006 Canada 2004 
Validation 
Cohort 6 445 . 58.0 68% 66% 18% 8% 
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Table 1. Continued 
Author Year Country 
Recruitment 
Start 
Cohort 
Characteristics 
Follow-up 
(Mths) 
Number of 
Access 
Upper Arm* 
(%) 
Age 
(years) 
Male 
(%) 
White 
(%) 
DM 
 (%) 
PVD 
 (%) 
Korten et al.60 2007 NLD 2000 Lower Arm . 148 0% 65.0 55% . 31% . 
Chan et al.24 2008 USA 1996 All . 318 . 62.2 53% 58% 53% 22% 
Dember et al.61 2008 USA 2003 Clopidogrel 6 385 47% 52.7 62% 50% 49% 4% 
Dember et al.61 2008 USA 2003 Placebo 6 373 45% 54.5 63% 54% 47% 3% 
Field et al.62 2008 UK 2003 Lower Arm . 210 0% 61.7 59% 94% 33% 31% 
Field et al.62 2008 UK 2003 Upper Arm . 79 100% 61.0 34% 94% 43% 47% 
Huijbregts et al.63 2008 NLD 2004 All 11 491 40% 64.6 62% 78% 33% 10% 
Peterson et al.64 2008 USA 2001 All . 205 55% . 60% 14%○ 52% 15% 
Pflederer et al.65 2008 USA 2004 All . 321 37% 64.5 65% . 43% . 
Pflederer et al.65 2008 USA 2004 AVF-T . 161 97% 63.3 61% . 45% . 
Koksoy et al.66 2009 Turkey 2003 AVF-T 28 50 100% 54.7 52% . 32% . 
Koksoy et al.66 2009 Turkey 2003 Upper Arm 28 50 100% 54.8 60% . 24% . 
Maya et al.67 2009 USA 2000 AVF-T . 67 100% 56.0 52% 16% 58% 12% 
Maya et al.67 2009 USA 2000 Upper Arm . 322 100% 56.0 48% 23% 53% 16% 
Weber et al.68 2009 Canada 2003 All . 125 54% 66.0 58% 54% 44% . 
Ferring et al.69 2010 UK 2006 Clinical . 101 37% . 66% 67% 34% 22% 
Ferring et al.69 2010 UK 2006 Ultrasound . 107 41% . 62% 71% 43% 14% 
Gonzalez et al.70  2010 USA 2007 AVF-T 11 33 100% 54.5 46% 70% 81% 6% 
Gonzalez et al.70 2010 USA 2007 Lower Arm 11 75 0% 54.3 52% 72% 56% 4% 
Gonzalez et al.70 2010 USA 2007 Upper Arm 11 35 100% 50.2 51% 75% 68% 3% 
Korkut & Kosem71 2010 Turkey 2004 AVF-T 48 350 100% 57.8 44% . 51% 30% 
Paul et al.72 2010 USA 2003 AVF-T 18 176 100% 61.0 34% . 52% . 
Pisoni et al.73 2010 USA 2000 No Statin . 218 100% 55.0 52% 23%○ 44% 16% 
Pisoni et al.73 2010 USA 2000 On Statin . 99 100% 58.0 39% 22%○ 75% 16% 
Ravani et al.74 2010 Italy 1997 All 42 473 18% 66.3 58% 98% 27% . 
Schenk75 2010 USA 2008 All . 131 83% . . . . . 
Jennings et al.76 2011 USA 2003 Elderly 17 461 38% 73.0 49% . 60%×× . 
Jennings et al.76 2011 USA 2003 Non-Elderly . 618 . 53.0 52% . 56%×× . 
Lee et al.77 2011 USA 2005 One1  . 54 70% . 70% 30% 56% 13% 
Lee et al.77 2011 USA 2005 ≥Two1  . 23 61% . 52% 13% 70% 39% 
Lee et al.77 2011 USA 2005 Zero1 . 96 69% . 82% 26% 43% 19% 
Swindlehurst et al.78 2011 UK 2000 Elderly 25 246 71% 74.0 62% 62% 41% . 
Swindlehurst et al.78 2011 UK 2000 Non-elderly 28 89 71% 49.0 55% 47% 29% . 
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Legend: *Upper Arm (%) refers to the percentage of upper arm fistulas in each cohort; DM= Diabetes; PVD= Peripheral 
Vascular Disease; ^Under Group column, “All” refers to the entire study cohort; ○Percentage Caucasian was estimated based 
on 78% of the patient population being African-American (i.e. not Black); ××Percentage of patients whose diabetes was the 
cause of renal failure. The actual proportion of diabetic patients in this cohort is likely higher than reported here. 
NLD=Netherlands; USA=United States. 
1Number of interventions conducted for each group 
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Table 2. Data extracted for each study 
Author Year 
Incident/ 
Prevalent 
Data 
Collection* 
Table/ 
Curve** 
Outcome 
  1-Year 2-Year 
PF PP SP FPP FSP PP SP FPP FSP 
Quintaliani et al.41  2000 Prevalent No C . . . . Y . . . . 
Wolowczyk et al.42 2000 Incident Yes T Y Y- . . . Y- . . . 
Allon et al.9 2001 Incident No C Y Y Y . . . . . . 
Gibson et al.43 2001 Incident No T . Y Y . . Y Y . . 
Dixon et al.10 2002 Incident No T Y Y Y . . Y Y . . 
Huber et al.44 2002 Incident Yes . Y . . . . . . . . 
Malovrh45 2002 Incident Yes . Y . . . . . . . . 
Pisoni et al.27 2002 Both No T . . . Y . . . . . 
Puskar et al.46 2002 Incident Yes C Y Y . . . Y . . . 
Ravani et al.47 2002 Incident Yes T Y- Y Y . . Y Y . . 
Feldman et al.48 2003 Incident Yes . Y- . . . . . . . . 
Bonforte et al.49 2004 Incident Yes C . Y- . . . Y- . . . 
Perera et al.50 2004 Incident No T Y Y- Y- . . Y- Y- . . 
Ravani et al.51 2004 Incident No C . . . Y . . . Y . 
Zeebregts et al.52 2004 Incident Yes C . Y Y . . . . . . 
Lok et al.53 2005 Incident No T Y Y Y . . Y Y . . 
Manns et al.54 2005 Incident No . Y- . . . . . . . . 
Vernaglione et al.55  2005 Incident Yes C . Y- . . . Y- . . . 
Wells et al.56 2005 Incident Yes T Y- Y- . . . . . . . 
Zeebregts et al.57 2005 Incident Yes T . Y Y . . Y Y . . 
Elsharawy et al.58  2006 Incident yes . Y . . . . . . . . 
Erkut et al.59 2006 Incident No T . Y- . . . Y- . . . 
Korten et al.60 2006 Incident No T Y- Y . . . . Y . . 
Lok et al.7 2006 Incident No . Y . . . . . . . . 
Huijbregts et al.63 2007 Incident Yes T Y Y Y Y Y . . . . 
Chan et al.24 2008 Incident No . Y- . . . . . . . . 
Dember et al.61 2008 Incident Yes . Y . . . . . . . . 
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Table 2. Continued 
                        
Author Year 
Incident/ 
Prevalent 
Data 
Collection* 
Table/ 
Curve** 
Outcome 
  1-Year 2-Year 
PF PP SP FPP FSP PP SP FPP FSP 
Field et al.62 2008 Incident No T . Y . . . Y . . . 
Peterson et al.64 2008 Incident No . Y . . . . . . . . 
Pflederer et al.65 2008 Incident No T Y- Y Y . . Y Y . . 
Koksoy et al.66 2009 Incident Yes T . . . Y Y . . . . 
Maya et al.67 2009 Incident No C Y . Y . Y . Y . Y 
Weber et al.68 2009 Incident Yes . Y . . . . . . . . 
Ferring et al.69 2010 Incident Yes C Y Y . . . . . . . 
Gonzalez et al.70  2010 Incident No . Y- . . . . . . . . 
Korkut & Kosem71 2010 Incident Yes T Y- . Y Y . . Y Y . 
Paul et al.72 2010 Incident No T . Y Y . . Y Y . . 
Pisoni et al.73 2010 Incident No C Y . Y . . . Y . . 
Ravani et al.74 2010 Incident No C . Y . . . Y . . . 
Schenk75 2010 Incident Yes . Y- . . . . . . . . 
Jennings et al.76 2011 Incident No T . Y- Y . . Y- Y . . 
Lee et al.77 2011 Incident No T Y- . . . Y . . . Y 
Swindlehurst et al.78 2011 Incident No T T Y Y . . . . . . 
Legend: *Was data collected prior to conception of study question?; **Patency reported within text or table format (T) vs. in a Kaplan-Meier curve (C); 
PP: Primary Patency; SP: Secondary Patency; FPP: Functional Primary Patency; FSP: Functional Secondary Patency; Y- refers to a study that reported 
the outcome of interest, however, the author(s) did not report a definition or the definition was not in accordance with our pre-specified definitions. 
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3.3.2 Patient population  
Patient demographic data, co-morbid conditions, and site of fistula creation were not 
always reported in the selected studies. However, when reported, the median age was 
58.9 years (range 36 to 74 years; IQR=9.2 years). The median proportion of men was 
58% (range 34 to 82%; IQR=13%). Within selected studies, the median proportion of 
patients with diabetes and peripheral vascular disease was 43% (range 0 to 81%; 
IQR=25%) and 16% (range 3 to 47%; IQR=12%), respectively.   
3.3.3 Risk of bias 
Many studies reported methods inadequately and definitions were inconsistent across 
studies. Appendix C lists definitions of primary failure reported in the included studies. 
When calculating the primary patency rate, fourteen studies included primary failures, six 
studies excluded primary failures, and eight studies did not report whether primary 
failures were included or excluded in their definition. Similarly, when calculating 
secondary patency, twelve studies included primary failures, six studies excluded primary 
failures, and five studies did not report the exclusion or inclusion of primary failures. 
When studies did not report the inclusion or exclusion of primary failure in the 
calculation of the patency rate, we assumed that primary failures were excluded. In 
sensitivity analyses, there were no differences in estimate of patency rates when we 
excluded studies that that did not report inclusion of primary failures. All studies were at 
moderate or high risk of bias in all domains assessed. The distribution of the components 
that described study quality is summarized in Table 3.  
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Table 3. Distribution of components describing study quality 
Component Number of Studies (%) 
Participation Bias 
How were participants recruited? 
Consecutive 30 (70%) 
Random 4   (9%) 
Stratified method 6   (14%) 
Not reported 3   (7%) 
Was enrolment based on pre-specified eligibility criteria? 
Yes 26 (61%) 
No 16 (37%) 
Not reported 1   (2%) 
Selection Bias 
Did follow-up begin at fistula creation or was fistula 
being used prior to study start? 
Fistula in place prior to the study start 4   (10%) 
Follow-up began at fistula creation 38 (88%) 
Not reported 1   (2%) 
Is it reported whether participants were eligible to 
different forms of fistulas? 
Yes 22 (51%) 
No 21 (49%) 
Attrition Bias 
Was loss-to-follow-up treated as censored observations 
(as opposed to missing)? 
Censored 28 (65%) 
Missing 6   (14%) 
Not reported 9   (21%) 
Was loss-to-follow-up reported for each cohort?* 
Yes  30 (51%) 
No 29 (49%) 
Proportion lost to follow-up* 
≤10% 22 (37%) 
>10% 8   (14%) 
Not reported 29 (49%) 
 
 
 
 
 
52 
 
Table 3. Continued 
Component Number of Studies(%) 
Measurement Bias 
Was the outcome definition based on published 
standardized definition4?  
Primary Failure 
Yes  18 (62%) 
No 11 (38%) 
Primary patency 
Yes  17 (71%) 
No 
 7   (29%) 
Secondary Patency 
Yes  15 (94%) 
No 1   (6%) 
Confounding 
Were at least age, sex, diabetes, and PVD considered or 
reported? 
Yes 20 (47%) 
No 23 (53%) 
Legend: *The number of cohorts reported rather than the number of studies. 
PVD=Peripheral vascular disease. 
3.3.4 Meta-Analysis 
3.3.4.1 Primary Failure  
The pooled estimate for primary failure among all studies was 27% (CI 23% to 32%) 
(Figure 6). This estimate must be interpreted cautiously given the high degree of 
heterogeneity (I2= 97%) amongst the studies. In subgroup analyses, the risk of primary 
failure was 28% (CI 20% to 37%) for lower arm and 26% (CI 19% to 34%) for upper arm 
fistulas. The risk of primary failure was 43% (CI 18% to 68%) among elderly and 32% 
(CI 13% to 51%) for non-elderly patients. The risk of primary failure was 30% (CI 24% 
to 36%) for North American and 23% (CI 17% to 28%) for European studies. When 
sources of heterogeneity were explored in meta-regression, we noted a trend towards an 
increase in the risk of primary failure among studies with a higher proportion of diabetic 
patients (p-value [p]=0.06).  
 Figure 6. Rates of primary fistula failure. Studies are ordered by ascending publication 
date. AVF= all types of fistulas; AVF
confidence limit; UCL= upper confidence limit.
-T= transposed arteriovenous fistula; LCL= lower 
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3.3.4.2 Primary Patency 
When including primary failure in the calculation for patency rate, the pooled primary 
patency rate was 59% (CI 53% to 64%) at one year and 47% (CI 39% to 55%) at two 
years (Figure 7). These estimates must again be interpreted cautiously given the high 
degree of heterogeneity amongst studies (I2>96%). In subgroup analyses (Table 4), there 
was no difference in the primary patency among fistula location (lower vs. upper arm) 
and study location (North America vs. Europe). We were unable to pool estimates of 
primary failure for the elderly and non-elderly due to insufficient number of observations. 
When sources of heterogeneity were explored in meta-regression, we noted a statistically 
significant decrease in the 1-year and 2-year patency rate among studies with a higher 
proportion of diabetic patients (p=0.006 and p=0.0004, respectively). We also noted a 
statistically significant decrease in the 2-year primary patency rate in studies which 
started recruitment in more recent years (p=0.05) and had a higher proportion of patients 
with upper arm fistulas (p=0.03).  
When the primary failure was not reported or excluded from the calculation of the 
patency rate, the pooled primary patency rate was 61% (CI 54% to 69%) at one year and 
46% (CI 38% to 55%) at two years. The pooled estimate for functional primary patency 
was 78% (CI 69% to 87%) at one year and 70% (CI 46% to 93%) at two years. 
Heterogeneity between studies was high (I2>95%). We noted a statistically significant 
decrease in the one- and two-year primary patency rate among studies with a higher 
proportion of diabetic patients (p=0.01 and 0.001, respectively) and more recent 
recruitment start date (p=0.001 and p=0.002, respectively).  
 
 Figure 7. Primary patency rates at one (a) and two (b) years for fistulas. Primary failures 
were included in the calculation of patency rate. Studies are ordered by ascend
publication date. “AVF= all types of fistulas; AVF
LCL= lower confidence limit; UCL= upper confidence limit.
-T= transposed arteriovenous fistula; 
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3.3.5 Secondary Patency  
When including the primary failure in the calculation of the patency rate, the pooled 
secondary patency rate was 66% (CI 58% to 74%) at one year and 58% (CI 49% to 68%) 
at two years (Figure 8). In subgroup analyses (Table 4), we found no difference in 
secondary patency rate among fistula location and study location. Once again, there was 
not an insufficient number of observations reporting on the elderly and non-elderly 
patients. Heterogeneity between studies was high (I2>97%). We noted a decrease in the 
1-year and 2-year secondary patency rate as the proportion of patients with diabetes 
increased (p=0.02 and p=0.02, respectively).  
When the primary failure was not reported or excluded from the calculation of the 
patency rate, the pooled secondary patency rate was 82% (CI 75% to 90%) at one year 
and 73% (CI 64% to 82%) at two years. The pooled functional secondary patency was 
78% (CI 69% to 87%) at one year and 70% (CI 60% to 81%) at two years. Heterogeneity 
between studies was high (I2>98%). In meta-regression analyses, we noted a statistically 
significant decrease in the 1-year secondary patency rates among studies with a higher 
proportion of men (p=0.01). However, there was a statistically significant increase in the 
1-year and 2-year secondary patency among studies with more recent recruitment start 
dates (p=0.001 and p=0.003, respectively).  
3.3.6 Sensitivity Analyses 
Our estimates of primary failure were unchanged when we analyzed cohorts that had 
≥100 number of fistulas, recruitment date ≥2000, and when the study question was asked 
before data collection (i.e. prospective design).   Appendix D shows sensitivity analyses 
for estimates of primary and secondary patency rates.   
 Figure 8. Secondary patency rates at one (a) and two (b) years for fistulas. Primary 
failures were included in the calculation of patency rate. 
publication date. AVF= all types of fistulas; AVF
LCL= lower confidence limit; UCL= upper confidence limit.
 
Studies are ordered by ascending 
-T= transposed arteriovenous fistula; 
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Table 4. Subgroup analyses 
Outcome Pooled Estimates 
1-Year 95% CI 2-Year 95% CI 
Primary Patency Rate- Primary failures included 
Lower Arm 55% 48% to 62% 45% 32% to 57% 
Upper Arm 59% 46% to 71% 43%^ 31% to 56% 
North America 55% 45% to 65% 41% 31% to 51% 
Europe 61% 56% to 67% 58% 53% to 63% 
Primary Patency Rate-Primary failures excluded or not reported 
Lower Arm 63% 44% to 81% 53% 31% to 75% 
Upper Arm 58% 44% to 73% 42% 24% to 60% 
North America 57% 50% to 64% 36% 29% to 42% 
Europe 61% 46% to 77% 50% 34% to 67% 
Secondary Patency Rate-Primary failures included 
Lower Arm 70% 59% to 81% 62% 49% to 76% 
Upper Arm 65% 56% to 74% 59% 48% to 69% 
North America 64% 53% to 76% 58% 47% to 69% 
Europe 69% 59% to 80% . . 
Secondary Patency Rate-Primary failures excluded or not reported 
Lower Arm . . . . 
Upper Arm 84% 76% to 93% 71% 61% to 82% 
North America 82% 72% to 92% 72% 60% to 85% 
Europe . . . . 
Legend: CI=Confidence interval; North America refers to studies conducted in Canada or United States; 
Europe refers to studies conducted in Croatia, England, Italy, Netherlands, or Slovenia; There was not 
sufficient number of cohorts to pool estimates for elderly and non-elderly patients. ^Fixed effects model 
was used to estimate patency rate. 
3.4 Discussion 
We conducted a comprehensive review of recent studies of hemodialysis fistula 
describing rates of primary failure, primary patency and secondary patency according to 
standardized definitions. There were two key findings: 1) approximately a quarter to one-
third of created fistulas failed to ever be used with an even higher risk in the elderly (>65 
years); and 2) by one year, over half of all fistulas failed or required at least one 
intervention (radiological or surgical). Indeed, we found a lower primary failure rate than 
previously reported for the contemporary patient population (previous literature has 
reported the primary failure to range between 30% and 70%). 
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Prior to 2000, fistulas tended to have acceptable risk of primary failure ranging between 
10% to 24%28–31 and one-year primary and secondary patency rates between 65% to 
94%30,32–34 and 85% to 90%35 respectively.  Using data from 1970 and 2002, Rooijens et 
al.36 reported a primary failure risk of 15% (CI 13% to 18%), a 62.5% (CI 54 to 70%) 
primary patency, and 66% (CI 58% to 73%) secondary patency rate at one year for 
radiocephalic (lower arm) fistulas. We obtained a higher risk of primary failure, as well 
as lower primary and secondary patency rates among lower arm fistulas (when primary 
failures were included).  However, when we excluded primary failures from the 
calculation of patency rate, we obtained a similar pooled estimate for one-year primary 
patency.  Compared to Rooijens et al., we examined all fistula locations and included 
only prospectively collected data. Our results show a significant decrease in fistula 
performance over time, with more current data highlighting a higher risk of primary 
failure and low to moderate primary and secondary patency rates.  
Given the significant heterogeneity in the study results, the pooled estimates must be 
applied judiciously to different types of patients and fistula procedures. We conducted 
meta-regression to examine the sources of heterogeneity, and found parameter estimates 
depended significantly on the proportion of diabetic patients and study recruitment date. 
At the study level, we could not attribute study differences in fistula outcomes to patient 
factors (age, sex, peripheral vascular disease). There may be other important factors not 
available in our data sources, such as vessel diameter and quality, surgical expertise, and 
differences in vascular access practices across programs, which may account for some of 
the differences.37–39  
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This review serves as a call to action to improve several key factors that impact vascular 
access choice, evaluation and management. First, the quality of reporting in future studies 
in this theme requires refinement and consistent application of standardized definitions. 
We found inconsistent reporting of definitions across studies and a high risk of potential 
bias. Study definitions, however, did not only suffer from inconsistent reporting, but also 
a lack of an objective definition that is easily benchmarked across studies and programs. 
For example, the exact time point of fistula use was not clearly defined across studies. 
Many definitions are used for defining successful fistula use, including single-needle 
versus two-needle cannulation, consistency of cannulation (e.g. three successive 
cannulations), having greater than 350 mL/min blood flow, and catheter removal. The 
“zero-time” for fistula use is not represented by a specific point in time. Since one 
objective of using a fistula is to avoid catheter use, the success of a fistula could be 
indicated by the time the catheter is removed or by not using a catheter at hemodialysis 
start.4 However, there are limitations in the precision of even this definition, as catheter 
removal may depend on other factors, such as available resources, which then potentially 
falsely lengthens the time of catheter dependence and delays the fistula use time. Our 
study highlights the importance of coming to a consensus amongst disciplines using an 
objective standard definition that can be used across studies to allow comparison of 
fistula outcomes. 
Our review has a number of strengths including rigorous methodology, consistency of 
one and two-year parameter estimates for patency rates, and it’s relevance to current 
practice and informing practice guidelines. Our review does have limitations. The 
screening of articles was conducted by a single individual, possibly contributing to study 
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selection bias. We only searched Medline and may be missing relevant studies only 
captured in Embase and/or Google Scholar. While we restricted this review to articles 
published in English, whether this introduced some bias is controversial.40  
In conclusion, we report a high risk of primary failure and low to moderate primary and 
secondary patency rates. There has been a significant decrease in fistula performance 
over time. These results may in part explain the decrease in fistula use in some countries. 
However, these results should be used judiciously because the quality of evidence for 
fistula performance is low and susceptible to bias.  
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4 Complication Rates of the Arteriovenous Fistula: A 
Systematic Review 
4.1 Introduction 
Previous studies have demonstrated the arteriovenous fistula (fistula) to be the preferred 
type of vascular access.1–3 Once established, the fistula has  longer patency and lower 
rates of complications compared to an arteriovenous grafts and catheters.4,5 However, 
with the increasing proportion of elderly and frail patients, the rate of failure to mature 
has increased with a decrease in patency rates.6–10 Other complications, related to 
vascular access, also deserve consideration to individualize patient risk, assist in 
providing informed consent, and to develop appropriate prevention and monitoring 
strategies. Complications are associated with morbidity, mortality, and high economic 
burden.11–14 To our knowledge, no published systematic review has evaluated fistula 
complication rates in terms of infections, ischemic steal syndrome and thrombosis rates 
in the contemporary hemodialysis population between 2000 and 2012. We conducted this 
systematic review to efficiently summarize current published information on the rates for 
abovementioned complications, as well as identify knowledge gaps in the existing 
literature.  
4.2 Methods 
We conducted and reported this systematic review according to published guidelines 
using a pre-specified protocol (PRISMA Checklist: Appendix G).15,16 Description of 
studies eligible for review, data sources, study selection, data abstraction and quality 
assessment used for this review have been reported elsewhere (Chapter 3: Methods).  
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Briefly, we included English-language studies indexed in MEDLINE that followed 
patients prospectively (observational cohort, randomized control trials, or surveillance 
programs) for a period of at least three months. We excluded any study that reported on 
less than 100 fistulas, or published results prior to January 1st 2000.  Two blinded and 
independent reviewers (A.A. and either J.C.Z., S.D.K., or S.M.T.) abstracted data from 
selected studies using a standardized form with a third reviewer adjudicating 
discrepancies. We assessed risk of bias using previously validated methods,17 and 
abstracted data on study methodology and cohort characteristics. All studies must have 
reported on at least one outcome of interest: a) rate of infection; b) rate of ischemic steal 
syndrome c) rate of thrombosis among incident and/or prevalent hemodialysis patients 
using a fistula.   
4.2.1 Study Definitions 
We used  outcome definitions in accordance with the Society of Vascular Surgery and the 
American Association of Vascular Surgery document as well as the North American 
Vascular Access Consortium (NAVAC) document (below).18,19 When definitions were 
not in agreement between the two documents, we used the NAVAC definitions. When 
the study definition was not in accordance with previously published definitions, we 
noted the differences in our tables. 
4.2.1.1 Outcome Definitions 
Infections: Definite or probable local vascular access infections, vascular access-related 
sepsis, bacteremia or a composite of these infections.  
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Ischemic steal syndrome: One or more clinical manifestations of: pain, ischemic 
neuropathy, ulceration, and gangrene felt to be related to a fistula diverting blood from 
the distal circulation resulting in a zone of arterial insufficiency in the tissues distal to the 
fistula.18 
Thrombosis: Absence of bruit or thrill, using auscultation and palpation, throughout 
systole and diastole at least 8 cm proximal to the arteriovenous anastomosis.18,19 
4.2.2 Summary Statistics 
We report the median and range for the event rate (per 1000 patient-days) of an outcome. 
Due to differences in sampled populations, outcome definitions, prevalence of co-morbid 
conditions, and variable sample selection criteria, it was not appropriate to calculate a 
summary statistic based on the weighted average. When the rates were not reported, we 
calculated the overall follow-up time (denominator) by multiplying the mean follow-up 
time by the number of patients. We used the overall follow-up time to calculate the event 
rate per 1000 patient-days. It is important to note that in using this method; we assumed 
that the hazard rate of developing a particular outcome was constant across individuals 
and over time.   
4.3 Results 
The literature search yielded 7,006 citations. All citations were screened and 459 full-text 
articles were assessed for eligibility. Twenty-six articles met eligibility criteria; however, 
three studies were excluded due to insufficient information on study design.20–22 Details 
of the study selection are shown in Figure 9. Three additional studies were identified 
through manual search of bibliographies of selected articles.23 Thus, 26 studies (34 
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unique cohorts; n≥ 6577 fistulas) were included from ten countries. Nine articles reported 
outcomes from the United States, five from Italy, three from Canada, and one each from 
Australia, Belgium, Iran, Israel, Jordan, Netherlands, Saudi Arabia, and Turkey. One 
study reported outcomes of interest across European countries.24 All studies were 
published between 2001 and 2011 with patient recruitment beginning between 1991 and 
2006. The characteristics of each study are described in Table 5. 
4.3.1 Patient population  
Patient demographic data, co-morbid conditions, and site of fistula creation were not 
always reported. However, when the data was reported, the median age was 61 years 
(range 48 to 73 years; IQR=7 years). The median proportion of men and patients with 
diabetes was 57% (range 27% to 71%; IQR=10%) and 35% (range 14% to 60%; 
IQR=21%), respectively. The median proportion of patients who had an upper arm fistula 
was 38% (range 0% to 100%; IQR=41%). The median proportion of patients who were 
Caucasian was 84% (range 62% to 100%; IQR=23%). 
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Figure 9. Flow diagram of study eligibility and inclusion. CKD= Chronic Kidney 
Disease 
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Table 5. Study Characteristics 
Author Year Country Recruitment Start 
Cohort 
Characteristics 
Follow-up 
(Mths) 
Number of 
Fistulas 
Upper 
Arm* 
(%) 
Age 
(years) 
Male 
(%) 
White 
(%) 
DM 
(%) 
PVD 
(%) 
Bonforte et al.25 2004 Italy 1991 Lower Arm 27 112 0% 71 50% . 22% . 
1Elseviers et al.24 2003 Europe 2003 All 12 1049 . . 56% 92% . . 
1Gilad et al.26 2005 Israel 2002 All . 143-161** . 63.5 55% . 48% . 
Huijbregts et al.5 2008 NLD 2004 All 11 491 40% 64.6 62% 78% 33% 10% 
Jennings et al.27 2011 USA 2003 ≥65 Years 17 461 38% 73 49% . 60%×× . 
Jennings et al.27 2011 USA 2003 ≤65 Years 18 618 . 53 52% . 56%×× . 
Korkut & Kosem28 2010 Turkey 2004 AVF-T 48 350 100% 57.8 44% . 51% 30% 
Labriola et al.29 2011 Belgium 2001 All 75 193 . 70.4 66% . 33% . 
Lok et al30 2003 Canada 1997 All 12 189 30% 57.5 71% 62% 22%×× . 
Mallamaci31 2005 Italy . All 33 205 5% 59.4 57% 100% 14% . 
1McCarley et al.32 2001 USA 1996 NM 11 39 . 55.3 51% 71% 36%×× . 
1McCarley et al.32 2001 USA 1996 DVPM 12 41 . 56.6 54% 70% 36%×× . 
1McCarley et al.32 2001 USA 1997 VABFM 10 43 . 56.1 59% 68% 34%×× . 
Paul et al.33 2010 USA 2006 endo/AVF-T 14 98 100% 60 40% . 52% . 
Paul et al.33 2010 USA 2003 open/AVF-T 18 78 100% 62 27% . 56% . 
Pflederer et al.7 2008 USA 2004 All . 321 37% 64.5 65% . 43% . 
Pflederer et al.7 2008 USA 2004 AVF-T . 161 97% 63.3 61% . 45% . 
2Polkinghorne et al.34 2006 Australia 2001 No Monitoring 16 68 34% 56.4 71% 97% 28% 7% 
2Polkinghorne et al.34 2006 Australia 2001 Monitoring 17 69 36% 60 65% 89% 35% 13% 
Qasaimeh et al.35 2008 Jordan 2004 All 7.6 105 . . . . . . 
Ravani et al.36 2002 Italy 1995 All 20 197 19% 65.7 59% . 22% . 
Roozbeh et al.37 2006 Iran . All 23£ 171 57% 53 68% . 27%×× . 
1Saxena et al.38 2003 Saudi Arabia 1997 All 6 102 . 47.5 54% . . . 
3Shahin et al.39 2005 USA 1992 No Monitoring 21 146 51% 54.9 58% 93% 49% 39% 
4Shahin et al.39 2005 USA 1999 Monitoring 19 76 61% 57.6 59% 90% 57% 53% 
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PVD= Peripheral vascular disease; All=all fistula locations; NLD=Netherlands; Lower arm= A cohort consisting of patients only fistulas located in the 
lower arm; NM=No monitoring; DVPM=Dynamic venous pressure monitoring; VABFM=vascular access blood flow monitoring; endo/AVF-T= A 
transposed arteriovenous fistula (AVF-T) created using an endoscopic procedure; open/AVF-T=A transposed arteriovenous fistula (AVF-T) created 
using a long open incision technique (open/AVF-T) 
1Note: Baseline characteristics were not provided specifically for patients with fistula. This information pertains to all types of accesses in the cohort. 
2 This is a randomized control trial comparing blood-flow surveillance by ultrasound dilution to standard clinical care.  
3Patients that did not receive access flow monitoring. 
4Patients who received regular access flow monitoring. 
5Tessitore et al. collected data in 159 haemodialysis patients with mature fistulas, 97 followed by unsystematic clinical monitoring (A) and 62 by adding 
Qa surveillance to monitoring (B). 
▪Only patients from postintervention group (0-6 months) were included here. 
**There were between 199 and 224 HD patients dialyzing at the author's centre with seventy-two percent of the follow-up time being contributed by 
those using a fistula. 
××Percentage of patients whose diabetes was the cause of renal failure. 
^Number of patients is estimated from patient-year-at-risk or dialysis-run-per-year from two studies. 
£ Roozbeh et al. reported a study period of 14-months, however, provided a mean follow-up time of 23 months. 
Table 5. Continued 
Author Year Country Recruitment Start 
Cohort 
Characteristics 
Follow-up 
(Mths) 
Number of 
Fistulas 
Upper 
Arm* 
(%) 
Age 
(years) 
Male 
(%) 
White 
(%) 
DM 
(%) 
PVD
(%) 
Taylor et al.40 2002 Canada 1998 All 6 >100 . . . . . . 
1Taylor et al.41 2004 Canada 1998 All 6 >100 . . . . 34% . 
Tessitore et al.42 2003 Italy 1998 All 7 120 0% 62.1 64% . 23% . 
5Tessitore et al.43 (A) 2008 Italy 2002 All . 97 18% 65.1 64% . 19% . 
5Tessitore et al.43 (B) 2008 Italy 2002 All . 62 21% 63.4 55% . 31% . 
Tokars et al.44 2001 USA 1997 All 6 130 . . . . . . 
Tokars et al.45 2002 USA 1999 All . >100 . . . . . . 
Zasuwa et al.46▪ 2010 USA 2003 All 6 104 . . . . . . 
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4.3.2 Study Quality Assessment 
Methods were inadequately reported and definitions were inconsistent across studies. 
Definitions were not reported for five out of thirteen studies reporting infections, all 
studies reporting ischemic steal syndrome, and eight out of thirteen studies on thrombosis 
(Figure 10). Appendix H lists definitions of infections and thrombosis amongst the 
included studies. Loss to follow-up was not reported in 17 out of 34 cohorts; however, 
when reported, the median loss to follow-up was 5% (range 0% to 17%; interquartile 
range [IQR]=6%). All studies were at moderate or high risk of bias in all domains 
assessed. The distribution of the components that described study quality is summarized 
in Table 6.  
From the studies that reported on infection: six reported on blood stream infections, four 
on all types of infections, four on vascular access-related infections, one on wound 
infection in the early post-operative period, one on infections requiring vascular access 
removal, and one on vascular access-related septicemia. Six out of the thirteen studies 
were prospective surveillance studies and generally did not report baseline characteristics 
specific to patients using a fistula.  
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Figure 10. Number of studies that used a standardized definition 
*We aggregated various types of infections; hence, it was not possible to use a standardized definition. However, eight out of ten 
studies provided a definition of infection.
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Table 6. Distribution of components describing study quality 
Component Number of Studies (%) 
Participation Bias  
How were participants recruited?  
Consecutive 16 (62%) 
Stratified method 4 (15%) 
Not reported 6 (23%) 
Was enrolment based on pre-specified eligibility criteria?  
Yes 11 (42%) 
No 15 (58%) 
Selection Bias  
Did follow-up begin at fistula creation or was fistula being used 
prior to study start? 
 
Fistula in place prior to the study start 19 (73%) 
Follow-up began at fistula creation 7 (27%) 
Is it reported whether participants were eligible to different forms of 
fistulas? 
 
Yes 5 (19%) 
No 21 (81%) 
Attrition Bias  
Was loss-to-follow-up reported for each cohort?*  
Yes 17 (50%) 
No 17 (50%) 
Proportion lost to follow-up*  
≤10% 13 (38%) 
>10% 4 (12%) 
Not reported 17 (50%) 
Measurement Bias  
Was the outcome definition similar to published standardized 
definition18,19? 
 
Infection**  
Yes 8 (61%) 
No 5 (39%) 
Ischemic Steal Syndrome  
Yes 0 (0%) 
No 5 (100%) 
Thrombosis  
Yes 4 (31%) 
No 9 (69%) 
Confounding  
Were at least age, sex, diabetes, and PVD considered or reported?  
Yes 4 (15%) 
No 22 (85%) 
*The number of cohorts reported rather than the number of studies. 
**We aggregated various types of infections; hence, it was not possible to use a standardized definition. 
However, eight out of the thirteen studies provided a definition of infection. 
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4.3.3 Incidence of Outcomes 
4.3.3.1 Infection:   
Thirteen studies reported the rate of infection for fourteen unique cohorts (Table 7). 
Among the four studies that examined all infections together, the median rate was 0.17 
infections per 1000 patient-days (ranged 0.06 and 0.39; IQR=0.12).7,23,24 The median rate 
for bloodstream infection was 0.09 events per 1000 patient-days (range 0.05 and 0.21; 
IQR=0.04) among six unique cohorts.23,26,29,40,41,45 The median rate for vascular access 
site infections was 0.4 events per 1000-patient days (range 0.02 to 1; IQR=0.55). When 
we aggregated all types of infections (i.e. composite infection rate), the median rate was 
0.11 infections per 1000 patient-days (range 0.01 to 1.0; IQR=0.13). 
4.3.3.2 Ischemic Steal Syndrome  
Five studies reported event rates of ischemic steal syndrome for seven unique cohorts 
(Table 7). The median rate of ischemic steal syndrome was 0.05 events per 1000 patient-
days (range 0 to 0.1; IQR= 0.03 events per 1000 patient-days). One study reported a rate 
of 0.1 events for elderly (>65 years) and 0.08 events per 1000 patient-days for non-
elderly individuals and found no difference in the event rate between the two groups (p-
value>0.05).27  Similarly, Lok et al.47 found no statistical difference (p-value=0.2) 
between the elderly and non elderly for ligation of fistula due to severe steal syndrome. 
Paul et al.33 compared the incident rate of steal syndrome in transposed fistula (AVF-T) 
created using an endoscopic procedure versus a long open incision. The authors reported 
an incident rate of zero and 0.05 events per 1000 patient-days for the two groups, 
respectively.    
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4.3.3.3 Thrombosis:  
Thirteen studies reported event rates of thrombosis in eighteen unique cohorts (Table 7). 
The median thrombosis rate was 0.27 events per 1000 patient-days (range 0.04 to 0.68; 
IQR=0.24). From the fifteen cohorts included, thirteen included only prevalent patients 
(patients already on  
Table 7. Infection, ischemic steal syndrome, and thrombosis rates per 1000 patient-days 
Author Site Incident/ 
Prevalent 
Number of 
Accesses 
Infection 
Rate** 
Steal 
Syndrome** 
Thrombosis 
Rate** 
Bonforte et al.25 Single Incident 112 . 0.02 0.14 
Elseviers et al.24 Multi Prevalent 1049 0.06• . 0.14 
Gilad et al.26 Single Prevalent 143-161** 0.05◊ . . 
Gilad et al.26 Single Prevalent 143-161** 0.02 . . 
Huijbregts et al.5 Multi Incident 491 . . 0.38 
Jennings et al.27 Single Incident 461 . 0.1 . 
Jennings et al.27 Single Incident 618 . 0.08 . 
Korkut & Kosem28 Single Incident 350 0.04^ 0.05 0.37 
Labriola et al.29 Single Prevalent 193 0.13◊ . . 
Lok et al30 Single Both 189 . . 0.33 
Mallamaci31 Multi Prevalent 205 . . 0.39 
McCarley et al.32 Multi Prevalent 39 . . 0.38 
McCarley et al.32 Multi Prevalent 41 . . 0.41 
McCarley et al.32 Multi Prevalent 43 . . 0.19 
Paul et al.33 Single Incident 98 . 0 . 
Paul et al.33 Single Incident 78 . 0.05 . 
Pflederer et al.7 Single Incident 321 0.14• . . 
Pflederer et al.7 Single Incident 161 0.19• . . 
1Polkinghorne et al.34 Single Prevalent 68 . . 0.12 
2Polkinghorne et al.34 Single Prevalent 69 . . 0.17 
Qasaimeh et al.35 Multi Prevalent 105 1 . . 
Ravani et al.36 Single Incident 197 0.01£ 0.05 . 
Roozbeh et al.37 Multi Prevalent 171 . . 0.31 
Saxena et al. Single Prevalent 102 0.06 . . 
3Shahin et al.39  Single Incident 76 . . 0.30 
4Shahin et al.39 Single Incident 146 . . 0.25 
Stevenson et al.23 Multi Prevalent 238^ 0.39• . . 
Stevenson et al.23 Multi Prevalent 238^ 0.09◊ . . 
Taylor et al.40 Multi Prevalent >100 0.09◊ . . 
Taylor et al.41 Multi Both >100 0.21◊ . . 
Tessitore et al.42 Multi Prevalent 120 . . 0.19 
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Tessitore et al.43 (A) Multi Prevalent 97 . . 0.10 
Tessitore et al.43 (B) Multi Prevalent 62 
 
 
0.04 
Tokars et al.44 Multi Prevalent 130 0.60 . . 
Tokars et al.45 Multi Prevalent >100 0.19 . . 
Tokars et al.45 Multi Prevalent >100 0.08◊ . . 
Zasuwa et al.46▪ Single Prevalent 104 . . 0.68 
**Rates are per 1000 patient-days; • Any infection; ◊ Bloodstream infections;   Vascular access site 
infection; ^ Wound infection in the early post-operative period; £ Infections requiring vascular access 
removal;   VA-related septicemia 
1 Blood-flow surveillance by standard clinical care. Additional data was provided by author. 
2 Blood-flow surveillance by ultrasound dilution. Additional data was provided by author. 
3Patients that did not receive access flow monitoring. 
4Patients who received regular access flow monitoring. 
hemodialysis) and therefore excluded thrombotic events that may have occurred during 
the fistula maturation period. Lok et al.47 compared the proportion of incident elderly and 
non-elderly patients who lost their access due thrombosis. The authors found no 
difference (p-value=0.7) in the proportion of patients who lost their fistula due to 
thrombosis between the two groups.  
4.4 Discussion 
Our review identified 34 unique cohorts that reported on the rate of infections, steal 
syndrome or thrombosis among patients using a fistula. We identified two important 
findings: 1) the contemporary rates of complications in the fistula; 2) the critical need for 
consistent reporting of complication rates to allow evaluation of these outcomes across 
studies. Despite the burden of vascular access complications on the healthcare system, 
there remains a poor consensus on the incidence rate and risk factors associated with 
fistula complications.  
The clinical practice guidelines for the National Kidney Foundation Kidney Disease 
Outcomes Quality Initiative (NKF/KDOQI) and Canadian Society of Nephrology (CSN) 
recommends that the infection rate should not exceed 0.01 events per patient-year ( 0.027 
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per 1000 patient-days).1,2 Based on the evidence from the current literature, the rate of 
infection was higher for 15 out of 17 cohorts compared to recommended rates proposed 
by practice guidelines. Compared to AV-grafts and catheters, fistulas have lower rates of 
infection and thrombotic events. Previous studies have shown that the rate of catheter 
infection can range between 0.05 to 0.18 per patient-year and depends on the duration of 
the catheter use.48,49 Similarly, AV-grafts are at high risk for infection.2,50 The rate of 
local and bacteremic infections for AV-grafts can range between 0.11 and 0.20 per 
patient-year. 51–54 
Ischemic steal syndrome is an important complication of fistulas; with significant 
implications including pain and loss of access function. Non-symptomatic physiological 
steal is common and can occur  in 70% for lower arm fistulas to 90% for upper arm 
fistulas.55,56  The NKF/KDOQI and CSN has no recommendations for target rates of 
ischemic steal syndrome. Previous studies have reported symptomatic ischemic steal 
occurrence to range between 1% to 2% for lower arm fistulas and 5% to 10% among 
patients using an upper arm fistula.57–62 We found that the rate of ischemic steal 
syndrome was similar to estimates reported in the NKF/KDOQI guideline (1% to 4% of 
patients) and other studies.2 When comparing the fistula to the AV-graft, it has been 
shown that there is a lower risk of ischemic steal syndrome. Previous reports have shown 
a two-fold lower risk of developing ischemic steal syndrome when comparing fistulas to 
AV-grafts.2,50,63  
Thrombosis is a common complication and it is a recognized cause of fistula loss. The 
current NKF/KDOQI and CSN guidelines recommend that center specific thrombosis 
rate for the fistula should not exceed 0.25 events per patient-year (0.69 per 1000 patient-
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days).64 Among studies included in our review, the thrombosis rates observed were 
generally lower than the target rates recommended by practice guidelines. Furthermore, 
the rates of thrombosis observed in studies prior to 2000 were also comparable to rates 
reported in our study.65,66 Compared to AV-grafts, fistulas have lower rates of thrombotic 
events. Previous reports have reported AV-graft thrombosis to exceeded 0.8 events per 
patient-year (2.2 events per 1000 patient-days).67–69  
Studies included in our review varied substantially in quality, outcome definitions, and 
characteristics of patient population. Accordingly, the rate of fistula complications varied 
and may reflect selection bias of study participants, differences in clinical practice, 
variable vascular access care and monitoring or surveillance across facilities, and variable 
case definitions. Despite published recommendations for standardized vascular access 
reporting,18,19 a number of studies failed to report definition of outcomes and only a 
smaller number of studies used published standardized definitions.  
This information on complication rates is critical to informing patient-physician decision 
making, patient consent, and guiding resource allocation for vascular access 
monitoring/surveillance. Having accurate information on fistula complications and 
patients at highest risk is important in making informed decisions and choosing the 
appropriate vascular access based on the risks.  Furthermore, identifying the risk factors 
and patients at highest risk for a complication, appropriate resources and monitoring can 
be allocated for these individuals. For example, the elderly and patients with history of 
hypertension, peripheral vascular disease, and diabetes are at high risk of developing 
ischemic steal syndrome and thrombosis. Special emphasis should be placed on closely 
monitoring these patients. The importance of this type of surveillance will increase as the 
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demographic changes in the dialysis population and there is a higher prevalence of frail 
patients.  Delay in treatment of complications can lead the patient experiencing pain, 
vascular access loss, catheter dependence, and increased patient morbidity and 
hospitalizations.  
 Our review has a number of strengths compared to prior narrative reviews on this topic. 
We conducted a comprehensive search of the literature and systematically identified 
relevant studies in accordance with published guidelines and a pre-specified protocol. To 
our knowledge, this is the first review that has examined the rates of fistula complications 
in the contemporary dialysis population. Previous narrative reviews have included studies 
from the 1970’s whose patients are different from current dialysis population. 
Furthermore, previous reviews limited their focus to upper arm fistulas and reported the 
risks of infections, ischemic steal syndrome, and thrombosis as opposed to the event 
rate.70–72  
Our study does have limitations. The screening of articles was conducted by a single 
individual, possibly contributing to study selection bias. Methodological differences 
between studies precluded a precise estimate of complication rates and the pooling of risk 
factors; it has been suggested that pooling results when not warranted may lead to 
misleading conclusions.73  We restricted this review to articles published in English and 
whether this introduced some bias is controversial.74 Our review focused on infection, 
ischemic steal, and thrombosis. Although we observed similar rates of ischemic steal and 
thrombosis practice guidelines, it should be noted that the majority of included studies 
utilized prevalent patients and therefore reported outcomes for functional fistulas. 
Fistulas that were lost due to primary failure from thrombosis were excluded (therefore 
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non-functional fistulas), potentially biasing the ischemic steal and thrombosis rates to a 
lower rate. Although there are a number of other fistula complications such as aneurysms, 
venous hypertension, bleeding, etc., we were unable to capture these complications due to 
poor reporting of these complications in the literature. Finally, when calculating event 
rates, we assumed a constant hazard ratio; however, it has been shown that the hazard 
ratio of fistula outcomes can vary over time, with higher hazard rates being observed 
within the first six months of dialysis.75 We attempted to stratify complication rates per 
time period (e.g. 0-6 months of access placement, 7-12 months of access placement, etc); 
however, such granular data was not available within selected studies. 
The quality of primary studies inherently limits the conclusions that can be drawn from 
this review. Risk factors for fistula complications which include patient comorbidities, 
vessel characteristics, surgeon’s experience, and nursing experience with cannulation 
were generally not reported. Additionally, factors on timing between fistula creation and 
fistula use, timing of vascular access interventions, and clinical monitoring/surveillance 
practices were also not reported. These variables may have explained some of the 
heterogeneity in the estimates of complication rates. The paucity in reporting of risk 
factors impairs our ability to identify patients at highest risk for complications.  
Based on knowledge gaps identified in our review, we make the following 
recommendations for future studies. First, we recommend studies report infection events 
by type of infection (e.g. bloodstream versus local access site infection). This will help 
quantify the true burden of specific types of infection among those using a fistula. For 
example, a local fistula infection should not be treated the same as a vascular access-
related bacteremia resulting in sepsis and hospitalization. Second, an understanding of the 
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incidence of infection, steal syndrome, and thrombosis is needed to guide sample size 
calculations in future clinical trials to ensure that they have adequate statistical power. 
For example, in a systematic review of clinical trials testing the efficacy of blood flow 
surveillance in reducing risk of access loss, the biggest limitation in current trials was  
inadequate statistical power to detect a difference between the intervention group and 
control group among prevalent patients.76 Third, there is a need for longer and larger 
cohort studies that reflect the contemporary dialysis population. Although we included 
large scale national surveillance studies, a major limitation was the absence of patient 
characteristics for those using a fistula. This limited our ability to compare the effect of 
patient characteristics on the complication rates of the fistula. Finally, to advance the 
quality of vascular access information, future studies need to utilize consistent definitions 
and reporting methods in accordance to accepted published standards.19,77 This will 
permit comparison of fistula outcomes across studies to provide better insight on the 
burden of fistula complications.  
4.5 Conclusions 
We found that the rate of thrombosis and ischemic steal was similar to rates in published 
reports and those recommended by NKF/KDOQI. However, the infections rate was much 
higher than the range recommended by NKF/KDOQI guidelines. We found marked 
variability in complications rates in part due to the poor quality of studies, significant 
heterogeneity of study populations, and inconsistent definitions. There is an urgent need 
to standardize methods for reporting outcomes and complications of vascular access in 
future clinical studies to get better insight on the rates of complications and estimate the 
burden of vascular access complications.   
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5 Conclusions and Future Directions 
5.1 Overview 
This thesis explores the performance of arteriovenous fistulas using prospective data 
published between 2000 and 2012. We conducted two systematic reviews to summarize 
patency and complication rates of the arteriovenous fistula, as well as assessed the data 
quality and identified knowledge gaps in the existing literature.      
5.2 Outcomes of the fistula 
Chapters 3 and 4 of this thesis examined the primary failure, patency rate, and 
complication rates among chronic hemodialysis patients using the fistula. In Chapter 3, 
we conducted a systematic review and meta-analysis that suggested fistulas had a high 
risk of primary failures, with approximately a quarter of all fistulas failing prior to 
starting hemodialysis. Furthermore, we found that fistulas had moderate to good primary 
and secondary patency rates at one and two years. There was high heterogeneity across 
studies in part explained by the proportion of patients with diabetes and recruitment start 
date of each study.  
Studies with a higher proportion of patients with diabetes tended to have decreased fistula 
performance in terms of primary failure, primary patency and secondary patency.  
Furthermore, we found that the primary patency or time from fistula creation to need for 
intervention or failure has decreased with time. We identified an era effect with better 
patency rates in patients recruited to studies at the start of the 1990’s compared to 2005-
2011. This could be partly explained by the increase in the proportion of elderly patients 
who are more likely to be frail and have a number of co-morbidities. Unlike primary 
patency, secondary patency rates tended to increase as study recruitment dates progressed 
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closer to 2012. This is likely attributed to the advances in intervention (radiological and 
surgical) techniques, as well as an increase in the proportion of programs conducting 
vascular access blood flow surveillance for vascular access thrombosis and early 
intervention for this complication.   
In Chapter 4, we examined the rates of infection, ischemic steal syndrome, and 
thrombosis among studies published between 2001 and 2012. We found that fistula 
complication rates were generally low. Thrombotic events were the most common fistula 
complications, followed by infection, and finally the occurrence of ischemic steal 
syndrome was rare. Our median estimate of thrombosis rate was approximately 3.5 times 
higher than the infection rate and 7.6 times higher than the rate of ischemic steal 
syndrome complications.  
5.3 Limitations and Knowledge gaps in the Current 
Literature 
As discussed in Chapters 3 and 4, the quality of evidence in the selected studies was 
generally low to moderate. There was a high risk of bias, especially selection bias and 
confounding by indication. This thesis highlights that data for fistula outcomes are 
substantially biased by pre-specified eligibility criteria.  Individuals who receive fistulas 
that mature sufficiently for dialysis are likely to be different from individuals for whom a 
fistula cannot be established before dialysis initiation.1 These differences may in part be 
attributed to insufficient pre-dialysis planning or exposure to pre-dialysis care, unsuitable 
vascular anatomy for access creation, or limited patient life expectancy.1,2 Furthermore, 
study populations were heterogeneous and reporting of potential confounders and study 
definitions were not always complete. Therefore it was not possible to adjust for known 
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confounders. The low quality of data limits our confidence in reporting complication 
rates and accurately estimating the burden of fistula complications. 
Lastly, one is left questioning if the small change in the patency (after excluding primary 
failure) and complication rates is just due to a change in the population at risk, with the 
patients at higher risks of complications dying early leaving a healthier population with a 
lower risk of complications. Although not discussed in the primary articles, the risk of 
death is likely to be highest around the initial period of starting dialysis (first 6 months).3 
This was not addressed in the primary studies; therefore, we were unable to account for 
the competing risk of death and observing the outcome of interest.  
5.4 Future Work 
Future epidemiologic and health services research can examine indicators that impact 
fistula creation and use (separately). Without this necessary information, the modification 
of other downstream factors will not yield change in the proportion of patients starting 
dialysis using the appropriate vascular access. There is an urgent need for large cohort 
studies that identify groups of patients who are eligible for fistula creation and patients 
with whom fistula creation should not be attempted. This knowledge can inform 
approaches/tactics to guide resource allocation and alter dialysis initiation practices.  
Future work in vascular access research should examine clinical and health system 
variables that are associated with fistula creation and use. Linked registry and health care 
databases in Ontario can be leveraged for the purpose of this research. These data sources 
can be used to assess the rates of fistula creation among hemodialysis patients using a 
fistula compared to those not using a fistula. Furthermore, these data sources can be used 
to assess the association between arteriovenous access creation and use with variables 
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including patient co-morbid conditions, number of surgical/radiological interventions 
required for first use, duration of pre-dialysis nephrology care, as well as dialysis facility 
size (number of patients), location (urban vs. rural) and type (community vs. hospital). 
Observing an association between clinical and facility level factors on fistula creations 
and subsequent use can play a critical role in establishing patient selection criteria, 
providing informed consent, follow-up of patients, and addressing short falls within the 
process of care.  
The Ontario Renal Network (ORN) has identified vascular access as a priority program 
and its main objective is to increase the rate of functioning complication-free vascular 
access.4 It is reasonable to leverage the rich existing health care databases in the province 
of Ontario for vascular access research. The large samples reflect routine clinical practice 
compared to existing small cohort studies. Linkage between billing and registry databases 
can enable accurate assessment of key exposures of interest and vascular access creation 
and use.  
5.5 Conclusion 
Rather than the fistula as the first choice, patient and center variables should be 
considered to ensure the choice of the appropriate vascular access for each patient. When 
considering the fistula, the initial high risk of maturation failure and complication rates 
should be considered alongside the long-term benefit of using this access. Given the high 
risk of primary failure, vascular access programs and policy makers should consider 
allocating sufficient resources and target preventive strategies around the timing of fistula 
creation and dialysis initiation period.  
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 It is important for nephrologists and healthcare stakeholders to recognize the 
performance and complication rates of the fistula. This information is critical for doctor-
patient decision making and can be used for clinical trials to determine the appropriate 
sample size calculations. However, these data should be used with caution because the 
current vascular access literature on fistula outcomes is comprised of low quality 
evidence.  
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Appendix A. MOOSE Checklist 
Criteria Brief description of how the criteria were handled in 
the meta-analysis 
Reporting of background should 
include 
 
√ Problem definition Chapter 3 Introduction, Paragraph 1 and 2: 
Fistula use is associated with fewer complications, 
improved vascular access survival, and lower risk of 
mortality compared to an arteriovenous graft (AV-graft) 
or central venous catheter (catheter).  
√ Hypothesis statement Chapter 3 Introduction, Paragraph 1: 
Fistulas are associated with a high risk of primary failure 
and low primary and secondary patency. 
√ Description of study outcomes Chapter 3 Introduction, Paragraph 2: 
Primary failure, primary patency (1- and/or 2-year), and 
secondary patency (1- and/or 2-year). 
√ Type of exposure or 
intervention used 
Fistula use 
√ Type of study designs used Chapter 3 Introduction, Paragraph 2: 
We included cohort studies that collected data 
prospectively (the study question could be derived prior 
to or after data collection). 
√ Study population Mean age ≥18 years in chronic kidney disease or end-
stage kidney disease patients. 
Reporting of search strategy 
should include 
 
√ Qualifications of searchers The credentials of the investigators (AA, LM, MO, AG, 
CL) who devised the search strategy is indicated in the 
author list. 
√ Search strategy, including time 
period included in the 
synthesis and keywords 
Chapter 3 Methods: 
PubMed was searched from January 2000 to June 2012 
√ Databases and registries 
searched 
Chapter 3  Methods: 
PubMed 
√ Search software used, name 
and version, including special 
features 
We did not employ a search software. Reference Manager 
was used to merge retrieved citations and eliminate 
duplications 
√ Use of hand searching Chapter 3 Methods: 
We hand-searched bibliographies of retrieved papers for 
additional references. 
√ List of citations located and 
those excluded, including 
justifications 
Details of the literature search process are outlined in the 
flow chart (Figure 1).  The citation list is available upon 
request 
√ Method of addressing articles 
published in languages other 
than English 
Chapter 3  Methods: Eligibility Criteria 
Only English-language articles were included. 
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√ Method of handling abstracts 
and unpublished studies 
We did not search gray literature  
√ Description of any contact with 
authors 
We did not contact any authors 
Reporting of methods should 
include 
 
√ Description of relevance or 
appropriateness of studies 
assembled for assessing the 
hypothesis to be tested 
Chapter 3 Methods: Eligibility Criteria 
Detailed inclusion and exclusion criteria were described 
in the methods section.  
√ Rationale for the selection and 
coding of data 
Chapter 3 Methods: Data Extraction and Quality 
Assessment 
Data extracted from each of the studies were relevant to 
the population characteristics, study design, exposure, 
outcome, and possible confounders. 
√ Assessment of confounding Restricted the analysis to studies published after 2000.  
Conducted subgroup analyses based on location of 
fistulas and American vs. European countries. We also 
conducted sensitivity analyses by eliminating studies that 
recruited patients before the year 2000, had less than 100 
fistulas in any one group, and those that collected data 
before derivation of study question.  
√ Assessment of study quality, 
including blinding of quality 
assessors; stratification or 
regression on possible 
predictors of study results 
See Table 3 
√ Assessment of heterogeneity Heterogeneity of the studies were explored using I2 
statistic which provides the relative amount of variance of 
the summary effect due to the between-study 
heterogeneity. 
√ Description of statistical 
methods in sufficient detail to 
be replicated 
Chapter 3 Methods: Data Analysis 
Description of methods of meta-analyses, sensitivity 
analyses, meta-regression and assessment of publication 
bias are described in the methods. 
√ Provision of appropriate tables 
and graphics 
Table 1.  Study Characteristics 
Table 2. Data extracted for each study 
Table 3. Distribution of components describing study 
quality 
Table 4. Subgroup analyses 
Figure 5.   Flow diagram of study eligibility and 
inclusion 
Figure 6 to 8. Forest Plots of our three outcomes 
Appendix B. Search strategy (OVID) 
Appendix C. Reported definition of primary access 
failures. 
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Appendix D. Sensitivity analyses 
 
Reporting of results should 
include 
 
√ Graph summarizing individual 
study estimates and overall 
estimate 
Figure 6 to Figure 8 
√ Table giving descriptive 
information for each study 
included 
Table 1 and Table 2 
√ Results of sensitivity testing 
 
Appendix D 
√ Indication of statistical 
uncertainty of findings 
95% confidence intervals were presented with all 
summary estimates and sensitivity analyses. 
Reporting of discussion should 
include 
 
√ Quantitative assessment of bias Sensitivity analyses indicate heterogeneity in strengths of 
the association due to most common biases in 
observational studies.   
√ Justification for exclusion We excluded non-English language articles, studies that 
reported on <100 fistulas, and published prior to 2000. 
Those studies that were excluded to improve study quality 
and provide fistula estimates on current dialysis 
population. 
√ Assessment of quality of 
included studies 
We discussed the results of the sensitivity analyses, and 
potential reasons for the observed heterogeneity. 
Reporting of conclusions should 
include 
 
√ Consideration of alternative 
explanations for observed 
results 
We discussed potential unmeasured confounders, such as 
condition of vasculature, which may have caused residual 
confounding.  
We noted that the variations in the strengths of 
association may be due to true population differences, 
residual confounding, or to differences in quality of 
studies. 
√ Generalization of the 
conclusions 
The present review can only be used to provide important 
insight on rates of fistula outcomes. However, actual 
estimates of fistula outcomes are likely to vary between 
centers. The majority of studies included were from the 
United States, and there were a minimal number of 
studies from Asia.  
√ Guidelines for future research Our study emphasizes the need for consistent reporting 
and the use of standardized objective definitions in future 
clinical studies.   
√ Disclosure of funding source No funding was obtained for the undertaking of this 
systematic review and meta-analysis. 
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Appendix B. Search strategy (OVID) 
1. exp renal dialysis/ or exp hemodiafiltration/ or exp hemodialysis, home/ or exp 
hemofiltration/ 
2. Kidney Failure, Chronic/ or *Aged/ or Renal Dialysis/ or *Adult/ or haemodialysis.mp. 
or *Middle Aged/ or exp Hemodialysis, Home/ 
3. Chronic Kidney Disease/ or renal dialysis/ or renal dialysis/ or renal dialysis/ or renal 
insufficiency/ or Dialysis Solutions/ or exp Renal Dialysis/ or Dialysis/ or dialysis.mp. 
[mp=protocol supplementary concept, rare disease supplementary concept, title, original 
title, abstract, name of substance word, subject heading word, unique identifier] 
4. Hemodialysis.mp. 
5. exp renal replacement therapy/ or exp renal dialysis/ or hemodiafiltration/ or 
hemodialysis, home/ 
6. 1 or 2 or 3 or 4 or 5 
7. vascular malformations/ or arteriovenous malformations/ or arteriovenous fistula/ or 
exp vascular fistula/ 
8. exp Arteriovenous Fistula/ or AVF.mp. 
9. exp Kidney Failure, Chronic/ or exp Renal Dialysis/ or AV-Fistula.mp. 
10. fistula.mp. or Arteriovenous Fistula/ or Arterio-Arterial Fistula/ or Brachial Fistula/ 
or Fistula/ or Vascular Fistula/ 
11. 7 or 8 or 9 or 10 
12. (epidemiology or (Staphylococcus aureus or Anti-Bacterial Agents)).mp. or exp 
infection/ or sepsis/ or exp bacteremia/ or shock, septic/ or wound infection/ or surgical 
wound infection/ or septicemia.mp. or exp sepsis/ or Enterococcus*.mp. [mp=protocol 
supplementary concept, rare disease supplementary concept, title, original title, abstract, 
name of substance word, subject heading word, unique identifier] 
13. Subclavian Steal Syndrome/ or Coronary-Subclavian Steal Syndrome/ or steal.mp. 
14. exp thrombosis/ or coronary thrombosis/ or exp thromboembolism/ or exp venous 
thrombosis/ or exp thrombophlebitis/ or upper extremity deep vein thrombosis/ 
15. exp Thrombosis/ or thrombosis.mp. or Cavernous Sinus Thrombosis/ or Carotid 
Artery Thrombosis/ or Upper Extremity Deep Vein Thrombosis/ or Venous Thrombosis/ 
or Coronary Thrombosis/ 
16. Vascular patency.mp. or exp Vascular Patency/ 
17. Vascular Patency/ or Ischemia/ or Graft Occlusion, Vascular/ or Primary patency.mp. 
18. secondary patency.mp. 
19. Arteriovenous shunt, surgical/mo or arteriovenous shunt, surgical/ae or arteriovenous 
shunt, surgical/sn or arteriovenous shunt, surgical/ or Vascular Patency/ or assisted 
patency.mp. 
20. Vascular Surgical Procedures/ or loss of patency.mp. 
21. 16 or 17 or 18 or 19 or 20 
22. 14 or 15 
23. 6 and 11 and 12 
24. 6 and 11 and 13 
25. 6 and 11 and 22 
26. 6 and 11 and 21 
27. 23 or 24 or 25 or 26 
28. limit 27 to (English language and yr="2000 - 2012") 
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Appendix C. Reported definition of primary access failures. 
Author Definition Comment 
Allon et al. 20011 An access that never achieved 
adequacy for dialysis. Fistula 
adequacy was defined prospectively as 
the ability to sustain hemodialysis with 
two needles and a blood flow of at 
least 350 mL/min on at least six 
dialysis sessions in one month. 
Patients were only followed for 
one month compared to our 
definition of 3 months.  
Chan et al. 20082 Failure to mature: fistula inadequate 
for hemodialysis use 
Did not define inadequacy. This 
definition includes immediate, 
early and late failures 
Dember et al. 20083 Fistula suitability was defined as the 
ability to use the fistula for dialysis 
with 2 needles and maintain a dialysis 
machine blood flow rate adequate for 
optimal dialysis (300 mL/min) during 
8 of 12 dialysis sessions occurring 
during a 30-day suitability 
ascertainment period. 
Examined early failures within 
one month 
Dixon et al. 20024 A fistula that failed before starting 
dialysis therapy, or if the patient 
started on dialysis therapy, had a 
catheter in place for dialysis for all but 
7 days of the cumulative life of the 
access. 
This definition captures 
immediate, early and late failures 
Elsharawy et al. 
20065 
Fistula thrombosis or an inability to 
cannulate both atrial and venous 
needles or to obtain sufficient dialysis 
blood flow (> 350 mL/min) within 8 
weeks after fistula creation 
This definition captures 
immediate and early failures 
within two months of access 
creation 
Feldman et al. 
20036 
Not able to use the access for dialysis 
more than 6 occasions for 
hemodialysis 
It was not clear if patients who 
never progressed to dialysis were 
considered as having an access 
failure. This definition captures 
immediate, early and late access 
failures. 
Ferring et al. 20107 A fistula that was never adequate for 
hemodialysis after initial surgical 
formation, including immediate failure 
on the day of surgery, early 
thrombosis, and failure to mature 
This definition captures 
immediate, early and late access 
failures. 
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Appendix C. Continued 
Author Definition Comment 
Gonzalez et al. 
20108 
Failed adequate maturation for 
initiation of dialysis 
Did not define inadequacy. This 
definition likely captures 
immediate, early and late access 
failures. 
Huber et al. 20029 Fistula that had not dilated 
significantly for cannulation despite 
remedial interventions were declared 
“failures” at 6 months even if they 
were still patent 
This definition captures 
immediate, early and late access 
failures. 
Huijbregts et al. 
200810 
A fistula that did not develop to 
maintain dialysis or thrombosed 
before the first successful cannulation 
for hemodialysis treatment, regardless 
of eventual AVF abandonment. 
 
 
This definition captures 
immediate, early and late access 
failures. 
Korkut & Kosem. 
201011 
Not reported No definition was reported 
Korten et al. 200712 Primary failure was defined as 
thrombosis of the radiocephalic or 
inadequate maturation, which resulted 
in inadequate dialysis access at 6 
weeks after surgery. 
 
 
This definition captures 
immediate and early failures 
within 6 weeks of access creation 
Lee et al. 201113 Not reported No definition was reported 
 
Lok et al. 200514 Fistulas that FTM were defined as 
those that met the following criteria: 
(1) did not develop enough by six 
months after creation to provide 
consistent dialysis for one month, and 
(2) this failure persisted despite efforts 
to facilitate its maturation (e.g., 
collateral vessel ligation) up to and 
including six months after creation. 
 
Lok et al. 200615 Fistula that was used for HD and was 
unable to provide prescribed dialysis 
via two-needle cannulation 
consistently for 1 month within 6 
months of its creation  despite 
interventions to facilitate maturation. 
This definition excludes technical 
failures. 
Excludes Immediate access 
failures 
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Table C. Continued 
Author Definition Comment 
Malovrh. 200216 Failed fistula function either 
immediately after construction or in 
the first 24 hours. 
Only immediate access failures 
were included within 24 hours of 
access creation 
Manns et al. 200417 Failing to cannulate the fistula with 
two needles on three consecutive runs 
with blood flow  300 ml/min 
Required three successive 
cannulations. This definition 
includes immediate, early and late 
failures. 
Maya et al. 200918 Inability to use the access successfully 
for dialysis, due to either early 
thrombosis or if it could be cannulated 
reproducibly for dialysis with two 
needles with a blood flow 300 ml/min 
for at least 1 month. 
This definition captures 
immediate and early failures 
within one month of access 
creation. 
Perera et al. 200419 Early failure within the first 90 days 
from the time of operation. Most of 
the failures were secondary to failure 
of the autogenous access to mature. 
This definition captures 
immediate and early failures 
within one month of access 
creation. 
 
 
Peterson et al. 
200820 
A fistula was considered mature when 
it could be cannulated reproducibly for 
dialysis, using two needles and 
achieving a dialysis blood flow 300 
ml/min, within 6 months of its 
creation. Failure to mature (primary 
failure) was defined as the inability to 
meet this goal. 
 
This definition captures 
immediate, early and late access 
failure. 
Pflederer et al. 
200821 
Abandonment of access before being 
used for dialysis 
A person with a functional fistula 
and not requiring dialysis would 
have been included in primary 
failures. This definition captures 
immediate, early and late failures. 
Pisoni et al. 201022 The inability to use the fistula 
successfully for dialysis because of 
early thrombosis or failure to mature 
Maya et al. used the same patient 
population and had expanded 
definition. This definition 
captures immediate and early 
failures within one month of 
access creation. 
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Appendix C. Continued 
Author Definition Comment 
Puskar et al. 200223 Failure of the arteriovenous fistula 
function within a month from its 
creation 
was considered an early arteriovenous 
fistula failure and after that period a 
late arteriovenous fistula failure. 
Did not define what failure of 
fistula entailed.  
Ravani et al. 200224 Fistula failure was defined as 
definitive clotting or malfunction 
caused by stenosis or partial 
thrombosis, usually suspected on the 
basis of inflow monitoring and 
dynamic pressure measurements and 
ascertained by recirculation studies, 
echo-power-Doppler, and 
fistulography, if necessary. This was 
the primary end point of the study, and 
if it occurred during the first 7 days 
after VA creation, it was considered an 
early failure. Failure to mature in the 
absence of these complications also 
was considered an early failure.  
It is unclear how the authors 
defined failure to mature. Also, 
the authors only captured early 
failures within 7 days of access 
creation 
Schenk. 201025 Primary failure was defined as 
occlusion or abandonment of a fistula 
before its successful entry into use for 
dialysis. 
A person with a functional fistula 
and not requiring dialysis would 
have been included in primary 
failures 
Swindlehurst et al. 
201126 
Immediate failure of fistula , early 
thrombosis, or failure to mature 
Authors used definition as 
reported by Sidawy et al.27 
Weber et al. 200928 The fistula did not matured in 3 
months by clinical examination or 
thrombosed prior to dialysis start 
This definition captures 
immediate and early failure 
Wells et al. 200529 Immediate failure of fistula or failure 
to mature. Successful maturation was 
achieved when the fistula was used on 
three successive occasions with  
adequate dialysis exchange 
Required three successive 
cannulations. This definition 
includes immediate, early and late 
failures. 
Wolowczyk et al.30 
2000 
Primary Failure was defined as: 1) an 
access that failed within 24 hours of 
fistula creation; 2) an early failure 
within 6 weeks, before the fistula 
could be used for hemodialysis; and 3) 
a late failure that was patent but never 
developed adequately to be used for 
hemodialysis by 6 weeks.  
A six week period may not be a 
sufficient period of time for all 
fistulas to mature. Authors did not 
define “adequately” used for 
dialysis.  
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Appendix D. Sensitivity analyses 
Subgroup One Year Two Year 
Primary Patency Estimate 
Lower 
95% CI 
Upper 
95% CI Estimate 
Lower 
95% CI 
Upper 
95% CI 
Primary Failure Included 
Number of fistulas ≥100 63% 60% 67% 51% 46% 57% 
Question derived before data collection 62% 54% 70% 60% 42% 78% 
Patients recruited ≥2000 55% 48% 63% 32% 11% 54% 
Primary Failure Excluded 
Number of fistulas ≥100 63% 55% 72% 49% 38% 60% 
Question derived before data collection 69% 46% 92% 56% 35% 78% 
Patients recruited ≥2000 52% 47% 57% 36% 29% 44% 
Secondary Patency   
Primary Failure Included    
Number of fistulas ≥100 69% 60% 79% 63% 51% 75% 
Question derived before data collection 75% 61% 89% - - - 
Patients recruited ≥2000 67% 55% 78% 50% 33% 67% 
Primary Failure Excluded   
Number of fistulas ≥100 85% 75% 94% 75% 65% 86% 
Question derived before data collection - - - - - - 
Patients recruited ≥2000 87% 79% 95% 77% 67% 88% 
CI= Confidence Interval; “-” refers to estimate unable to be calculated due to insufficient number of 
observations.  
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Appendix E. Contributions Chapter 3 
 Al-Jaishi had full access to all of the data in the study and takes responsibility for the 
integrity of the data and the accuracy of the data analysis.  
Study concept and design: Al-Jaishi, Moist, Oliver, Lok, and Garg; 
 Literature search and articles retrieval: Al-Jaishi, Moist, Oliver, Lok, and Garg;  
Data extraction and classification: Al-Jaishi, Thomas, Zhang, Kosa;  
Data analyses and interpretation: Al-Jaishi, Moist, Thomas;  
Manuscript drafting: Al-Jaishi and Moist;  
Critical revision of the manuscript for important intellectual content and final approval: 
Al-Jaishi, Moist, Oliver, Thomas, Lok, Zhang, Garg, and Quinn;  
Study supervision: Al-Jaishi and Moist had full access to all of the data and had the final 
responsibility to submit the manuscript for publication. 
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Appendix G.PRISMA checklist 
Section/topic  # Checklist item  Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  Page 71 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of 
key findings; systematic review registration number.  
N/A 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  Page 71 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
Page 71 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
       - 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
Page 
71,72 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
Page 
71,72 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  Appendix 
B  
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
Page 39-
41, 71,72 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
Page 
41,42 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
Page 
41,42 
Risk of bias in individual studies  12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at 
the study or outcome level), and how this information is to be used in any data synthesis.  
Page 
41,42 
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Section/topic  # Checklist item  
Reported 
on page 
#  
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  Page 73 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., 
I2) for each meta-analysis.  
Page 73 
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting 
within studies).  
Page 72 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
None 
conducted 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each 
stage, ideally with a flow diagram.  
Page 73, 
74 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
Page 74 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Not 
reported 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention 
group (b) effect estimates and confidence intervals, ideally with a forest plot.  
Page 76,77 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  Page 81-83 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  Page 78-80 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  None 
Conducted 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key 
groups (e.g., healthcare providers, users, and policy makers).  
Page 84-88 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
Page 86,87 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  Page 88 
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Appendix H. Reported definition for infection and thrombosis by study. 
Author Year Infection Rate** Thrombosis Rate** 
Bonforte et al.1 2004 
. Not reported 
Elseviers et al.2 2003 Not reported Not reported 
Gilad et al.3 2005 Centers for Disease Control definition . 
Huijbregts et al.4 2008 . Not reported 
Jennings et al.5 2011 . . 
Korkut & Kosem6 
2010 Wound infection in the early post-
operative period. Authors did not 
report how infection was defined. Not reported 
Labriola et al.7 
2011 Infectious events included both 
unexplained bacteremia caused by 
skin bacteria and/or local fistula 
infection. Local fistula infection 
was defined as nonallergic 
erythema, pain or tenderness close 
to cannulation sites, necrotic scabs, 
or drainage from cannulation 
site(s) 
. 
Lok et al8 
2003 
. 
Fistulas that demonstrated evidence 
of stenosis by two of three criteria 
(abnormal physical exam, elevated 
venous pressures or abnormal 
monthly recirculation studies) were 
referred for a Duplex US exam. If the 
Duplex US study of either an fistula 
found a severe stenosis, indicating a 
lesion of >50%, a referral for an 
angiogram was made. 
Mallamaci9 
2005 
. 
A sudden cessation of function of the 
fistula, rendering hemodialysis 
impossible and requiring 
thromboctemy, thrombolysis, or 
acute placement of another 
hemodialysis access. 
McCarley et al.10 2001 . Not reported 
Paul et al.11 2010 
. . 
Pflederer et al.12 2008 Not reported . 
1Polkinghorne et 
al.13 
2006 
. Not reported 
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Qasaimeh et al.14 
2008 Infection of the VA was 
considered positive when the 
access site became red, hot, tender 
and swollen, with or without 
discharge, or when the patient 
presented with fever or 
chills and the condition 
necessitated giving antibiotics, and 
ended in cure or cessation of use of 
the access. Signs could be in the 
blood stream resulting in fever and 
chills. Infection in fistula was 
wither an initial placement wound 
infection, a late localized puncture 
site infection, a declot wound 
infection, or a systemic bacteremia. 
. 
Ravani et al.15 2002 Not reported . 
Roozbeh et al.16 2006 . Complete vascular access occlusion 
Saxena et al. 2003 Not reported . 
3Shahin et al.17  2005 
. 
A fistula was determined to have 
thrombosed if it failed without other 
explanation (e.g., ligation for 
ischemia) or if a procedure was 
needed to remove thrombus at the 
time of access intervention. 
Stevenson et al.18 2002 CDC definition . 
Taylor et al.19 2002 Health Canada Definition . 
Taylor et al.20 2004 Health Canada Definition . 
Tessitore et al.21 2003 . Not reported 
Tessitore et al.22 (A) 
2008 
. Not reported 
Tokars et al.23 
2001 Local signs of pus or redness at the 
vascular access site or a positive 
blood culture with no known 
source other than the vascular 
access, and hospitalization or 
receipt of an IV antimicrobial 
. 
Tokars et al.24 
2002 Centers for Disease Control 
definition . 
Zasuwa et al.25 2010 
. 
Clinical staff documenting the 
inability to conduct hemodialysis by 
failure to obtain sufficient blood flow 
and confirmed by physical 
examination or endovascular 
evaluation 
 “.” Indicate that the study did not report this complication. “Not reported” indicates that the study reported 
the complication but not the definition. 
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Manuscript drafting: Al-Jaishi and Moist;  
Critical revision of the manuscript for important intellectual content and final approval: 
Al-Jaishi, Moist, Oliver, Thomas, Lok, Zhang, Garg, and Quinn;  
Study supervision: Al-Jaishi and Moist had full access to all of the data. 
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